Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page URLs for STN Seminar Schedule - N. America
NEWS 2		"Ask CAS" for self-help around the clock
NEWS 3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS 4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS 5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS 6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS 7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS 8	JAN 30	Saved answer limit increased
NEWS 9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS 10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS 11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS 12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS 13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS 14	FEB 28	TOXCENTER reloaded with enhancements
NEWS 15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS 16	MAR 01	INSPEC reloaded and enhanced
NEWS 17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS 18	MAR 08	X.25 communication option no longer available after June 2006
NEWS 19	MAR 22	EMBASE is now updated on a daily basis
NEWS 20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS 21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS 22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS 23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS 24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS 25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 11:49:40 ON 25 APR 2006

=> ile registry
ILE IS NOT A RECOGNIZED COMMAND
The previous command name entered was not recognized by the system.
For a list of commands available to you in the current file, enter
"HELP COMMANDS" at an arrow prompt (=>).

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 11:49:49 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0
DICTIONARY FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

****
* *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added, *
* effective March 20, 2005. A new display format, IDERL, is now *
* available and contains the CA role and document type information. *
* *
****

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10619662query.str



chain nodes :
7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23
ring nodes :
1 2 3 4 5 6
chain bonds :
1-23 2-7 6-8 7-10 7-11 8-9 8-12 11-13 11-16 12-14 12-15 15-17 15-21
15-22 16-18 16-19 16-20
ring bonds :
1-2 1-6 2-3 3-4 4-5 5-6
exact/norm bonds :
1-2 1-6 2-3 3-4 4-5 5-6 7-10 7-11 8-9 8-12 11-16 12-15 15-17 16-18
exact bonds :
1-23 2-7 6-8 11-13 12-14 15-21 15-22 16-19 16-20

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:CLASS 8:CLASS 9:CLASS 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:Atom 18:Atom
19:CLASS 20:CLASS 21:CLASS 22:CLASS 23:CLASS

L1 STRUCTURE UPLOADED

=> s L1
SAMPLE SEARCH INITIATED 11:50:07 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 391 TO ITERATE

100.0% PROCESSED 391 ITERATIONS 2 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 6634 TO 9006
PROJECTED ANSWERS: 2 TO 124

L2 2 SEA SSS SAM L1

=> d L2 1-2

L2 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 544678-73-1 REGISTRY
ED Entered STN: 09 Jul 2003
CN 2,4-Pyridinedicarboxamide, N,N'-bis[(3-methylphenyl)methyl]-,
monohydrochloride (9CI) (CA INDEX NAME)
MF C23 H23 N3 O2 . Cl H
SR CA
LC STN Files: CA, CAPLUS, USPAT2, USPATFULL
CRN (747406-86-6)



● HCl

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L2 ANSWER 2 OF 2 REGISTRY COPYRIGHT 2006 ACS on STN
RN 449734-45-6 REGISTRY
ED Entered STN: 12 Sep 2002
CN 2,4-Pyridinedicarboxamide, N,N'-bis([1,1'-biphenyl]-2-ylmethyl)- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN Pyridine-2,4-dicarboxylic acid bis[[(biphenyl)-2-ylmethyl]amide]
FS 3D CONCORD
MF C33 H27 N3 O2
SR CA
LC STN Files: CA, CAPLUS, TOXCENTER, USPAT2, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> sel L2
E1 THROUGH E3 ASSIGNED

=> file caplus medline biosis

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	5.34	5.55

FILE 'CAPLUS' ENTERED AT 11:50:42 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'MEDLINE' ENTERED AT 11:50:42 ON 25 APR 2006

FILE 'BIOSIS' ENTERED AT 11:50:42 ON 25 APR 2006
Copyright (c) 2006 The Thomson Corporation

=> s E1-E3
L3 2 ("PYRIDINE-2,4-DICARBOXYLIC ACID BIS((BIPHENYL)-2-YLMETHYL)AMIDE)"/BI OR 449734-45-6/BI OR 544678-73-1/BI)

=> d L3 1-2 ti abs bib

L3 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2,4-pyridinedicarboxamides and 4,6-pyrimidinedicarboxamides as inhibitors of collagenase (MMP 13)
GI



I

AB Title compds. [I; A = CH, N; R1-R3 = H, halo, (halogenated) alkyl, alkoxy, OH, CO2R4, cyano, NR5R6, etc.; R4 = H, alkyl; R5, R6 = H, alkyl, alkylcarbonyl, etc.; or R1R2, R2R3 = 5-6 membered (aromatic) (saturated) (hetero)cyclyl], were prepd for the treatment of degenerative joint diseases. Thus, 4,6-pyrimidinedicarboxylic acid in SOCl2 was stirred for 2 h at 85° followed by addition of CH2Cl2 at room temperature and Et3N at 0°. The reaction mixture was further stirred with 3-chloro-4-fluorobenzylamine for 15 min to give 40% N,N-bis(3-chloro-4-fluorobenzyl)pyrimidine-4,6-dicarboxamide. The latter inhibited collagenase 3 (MMP 13) with IC50 = 23 nM.
AN 2003:467290 CAPLUS
DN 139:53028
TI Preparation of 2,4-pyridinedicarboxamides and 4,6-pyrimidinedicarboxamides as inhibitors of collagenase (MMP 13)
IN Habermann, Joerg; Weithmann, Klaus-Ulrich; Kogler, Herbert; Kirsch, Reinhard; Wehner, Volkmar
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10160357	A1	20030618	DE 2001-10160357	20011208
	CA 2469625	AA	20030619	CA 2002-2469625	20021125
	WO 2003049738	A1	20030619	WO 2002-EP13240	20021125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002358535	A1	20030623	AU 2002-358535	20021125
	EP 1455790	A1	20040915	EP 2002-792799	20021125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005513049	T2	20050512	JP 2003-550787	20021125
	US 2003229103	A1	20031211	US 2002-65994	20021209
	US 6933298	B2	20050823		
PRAI	DE 2001-10160357	A	20011208		
	US 2002-358887P	P	20020222		
	WO 2002-EP13240	W	20021125		

OS MARPAT 139:53028

L3 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of pyridinedicarboxamide and -dicarboxylic acid derivatives as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses
GI



I

AB Selective MMP-13 inhibitors are pyridine derivs. (I; e.g. pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)) or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are H, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the N to which they are attached complete a 3- to 8-membered ring containing C atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6. Although I and other Markush structures in the patent show 2,4- derivs., many specific 3,5- derivs. are included in the claims and examples. Combinatorial and non-combinatorial methods were used to prepare numerous claimed compds. and characterization data is reported for about 90 compds. IC50 values for various claimed compds. show the selectivity towards MMP-13 vs. MMP-1 and MMP-3 and the potent MMP-13 inhibitory activity (e.g. 0.033 μM for pyridine-2,4-dicarboxylic acid bis[((1,3-benzodioxol-5-yl)methyl)amide]).
AN 2002:637657 CAPLUS
DN 137:185420
TI Preparation of pyridinedicarboxamide and -dicarboxylic acid derivatives as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses
IN Barvian, Nicole Chantel; Connor, David Thomas; O'brien, Patrick Michael; Ortwine, Daniel Fred; Patt, William Chester; Shuler, Kevon Ray; Wilson, Michael William
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064568	A1	20020822	WO 2002-IB345	20020204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434982	AA	20020822	CA 2002-2434982	20020204
EP 1362033	A1	20031119	EP 2002-716263	20020204
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

```
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     EE 200300391          A     20031215    EE 2003-391             20020204
     BR 2002007863         A     20040427    BR 2002-7863            20020204
     JP 2004529878         T2    20040930    JP 2002-564501          20020204
     CN 1537101            A     20041013    CN 2002-804945          20020204
     US 2002161000         A1    20021031    US 2002-71073           20020208
     US 6881743            B2    20050419
     ZA 2003006041         A     20041105    ZA 2003-6041            20030805
     NO 2003003570         A     20030812    NO 2003-3570            20030812
     BG 108089             A     20050131    BG 2003-108089          20030813
     US 2004209922         A1    20041021    US 2004-842863          20040510
     US 7015237            B2    20060321
PRAI US 2001-268781P       P     20010214
     WO 2002-IB345         W     20020204
     US 2002-71073         A3    20020208
OS   MARPAT 137:185420
RE.CNT  10    THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
              ALL CITATIONS AVAILABLE IN THE RE FORMAT


=> file uspatfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    31.06      36.61

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -1.50      -1.50

FILE 'USPATFULL' ENTERED AT 11:52:38 ON 25 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE COVERS 1971 TO PATENT PUBLICATION DATE: 20 Apr 2006 (20060420/PD)
FILE LAST UPDATED: 20 Apr 2006 (20060420/ED)
HIGHEST GRANTED PATENT NUMBER: US7032245
HIGHEST APPLICATION PUBLICATION NUMBER: US2006085880
CA INDEXING IS CURRENT THROUGH 20 Apr 2006 (20060420/UPCA)
ISSUE CLASS FIELDS (/INCL) CURRENT THROUGH: 20 Apr 2006 (20060420/PD)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Feb 2006
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Feb 2006


=> s E1-E3
        144459 "PYRIDINE"/BI
       4429129 "2"/BI
       4369219 "4"/BI
         72135 "DICARBOXYLIC"/BI
        840420 "ACID"/BI
        221352 "BIS"/BI
         41674 "BIPHENYL"/BI
       4429129 "2"/BI
         12843 "YLMETHYL"/BI
        153431 "AMIDE"/BI
             4 "PYRIDINE-2,4-DICARBOXYLIC ACID BIS(((BIPHENYL)-2-YLMETHYL)AMIDE
               )"/BI
                 (("PYRIDINE"(W)"2"(W)"4"(W)"DICARBOXYLIC"(W)"ACID"(W)"BIS"(W)"
                 BIPHENYL"(W)"2"(W)"YLMETHYL"(W)"AMIDE")/BI)
             0 449734-45-6/BI
             0 544678-73-1/BI
L4           4 ("PYRIDINE-2,4-DICARBOXYLIC ACID BIS(((BIPHENYL)-2-YLMETHYL)AMID
               E)"/BI OR 449734-45-6/BI OR 544678-73-1/BI)

=> d L4 1-4 ti abs bib

L4   ANSWER 1 OF 4  USPATFULL on STN
```

TI Pyridine matrix metalloproteinase inhibitors
AB Selective MMP-13 inhibitors are pyridine derivatives of the formula ##STR1##

or a pharmaceutically acceptable salt thereof,

wherein:

R.sup.1 and R.sup.2 independently are hydrogen, halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, N0.sub.2, NR.sup.4R.sup.5, CN, or CF.sub.3;

E is independently O or S;

A and B independently are OR.sup.4 or NR.sup.4R.sup.5;

R.sup.4 and R.sup.5 independently are H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, (CH.sub.2).sub.n aryl, (CH.sub.2).sub.n cycloalkyl, (CH.sub.2).sub.n heteroaryl, or R.sup.4 and R.sup.5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer of from 0 to 6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:268379 USPATFULL
TI Pyridine matrix metalloproteinase inhibitors
IN Barvian, Nicole Chantel, Ann Arbor, MI, UNITED STATES
Connor, David Thomas, Ann Arbor, MI, UNITED STATES
O'Brien, Patrick Michael, Stockbridge, MI, UNITED STATES
Ortwine, Daniel Fred, Saline, MI, UNITED STATES
Patt, William Chester, Chelsea, MI, UNITED STATES
Wilson, Michael William, Ann Arbor, MI, UNITED STATES
PI US 2004209922 A1 20041021
US 7015237 B2 20060321
AI US 2004-842863 A1 20040510 (10)
RLI Division of Ser. No. US 2002-71073, filed on 8 Feb 2002, PENDING
PRAI US 2001-268781P 20010214 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 13
ECL Exemplary Claim: CLM-001-9
DRWN No Drawings
LN.CNT 1657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 2 OF 4 USPATFULL on STN
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
AB This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an

allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a combination comprising an NSAID, or a pharmaceutically acceptable salt thereof, and an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-1 or cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. The invention combinations may also be further combined with other pharmaceutical agents depending on the disease being treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:25212 USPATFULL
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
IN Roark, William Howard, Ann Arbor, MI, UNITED STATES
PI US 2004019054 A1 20040129
AI US 2003-619769 A1 20030715 (10)
PRAI US 2002-396785P 20020717 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8368
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 3 OF 4 USPATFULL on STN
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AB This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:25211 USPATFULL

TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
IN Roark, William Howard, Ann Arbor, MI, UNITED STATES
PI US 2004019053 A1 20040129
AI US 2003-619662 A1 20030715 (10)
PRAI US 2002-396903P 20020717 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8040
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L4 ANSWER 4 OF 4 USPATFULL on STN
TI Pyridine matrix metalloproteinase inhibitors
AB Selective MMP-13 inhibitors are pyridine derivatives of the formula ##STR1##

or a pharmaceutically acceptable salt thereof,

wherein:

R.sup.1 and R.sup.2 independently are hydrogen, halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, NO.sup.2, NR.sup.4R.sup.5, CN, or CF.sub.3,

E is independently O or S;

A and B independently are OR.sup.4 or NR.sup.4R.sup.5;

R.sup.4 and R.sup.5 independently are H. C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, (CH.sub.2).sub.n aryl, (CH.sub.2).sub.n cycloalkyl, (CH.sub.2).sub.n heteroaryl, or R.sup.4 and R.sup.5 when taken together with the nitrogen to which they are attached complete a 3 to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted,

n is an integer of from 0 to 6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:288130 USPATFULL
TI Pyridine matrix metalloproteinase inhibitors
IN Barvian, Nicole Chantel, Ann Arbor, MI, UNITED STATES
Connor, David Thomas, Ann Arbor, MI, UNITED STATES
O'Brien, Patrick Michael, Stockbridge, MI, UNITED STATES
Ortwine, Daniel Fred, Saline, MI, UNITED STATES
Patt, William Chester, Chelsea, MI, UNITED STATES
Shuler, Kevon Ray, Chelsea, MI, UNITED STATES
Wilson, Michael William, Ann Arbor, MI, UNITED STATES
PI US 2002161000 A1 20021031
US 6881743 B2 20050419
AI US 2002-71073 A1 20020208 (10)
PRAI US 2001-268781P 20010214 (60)
DT Utility
FS APPLICATION
LREP Claude F. Purchase, Jr., Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI, 48105
CLMN Number of Claims: 35
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1991
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

```
=> file uspgpubs
'USPGPUBS' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'USPATFULL'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file pgpub
'PGPUB' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'USPATFULL'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file uspgpub
'USPGPUB' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'USPATFULL'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file pctfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                    12.29      48.90

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.50

FILE 'PCTFULL' ENTERED AT 11:54:09 ON 25 APR 2006
COPYRIGHT (C) 2006 Univentio

FILE LAST UPDATED:         25 APR 2006      <20060425/UP>
MOST RECENT UPDATE WEEK:       200616        <200616/EW>
FILE COVERS 1978 TO DATE

>>> IMAGES ARE AVAILABLE ONLINE AND FOR EMAIL-PRINTS <<<

>>> NEW IPC8 DATA AND FUNCTIONALITY NOW AVAILABLE IN THIS FILE.
    SEE
    http://www.stn-international.de/stndatabases/details/ipc-reform.html >>>

>>> FOR CHANGES IN PCTFULL PLEASE SEE HELP CHANGE
    (last updated April 10, 2006) <<<

=> s E1-E3
         43187 "PYRIDINE"/BI
       1001528 "2"/BI
        984281 "4"/BI
         16650 "DICARBOXYLIC"/BI
        266611 "ACID"/BI
        204039 "BIS"/BI
         15856 "BIPHENYL"/BI
       1001528 "2"/BI
          8080 "YLMETHYL"/BI
         60149 "AMIDE"/BI
             0 "PYRIDINE-2,4-DICARBOXYLIC ACID BIS(((BIPHENYL)-2-YLMETHYL)AMIDE
               )"/BI
                 (("PYRIDINE"(W)"2"(W)"4"(W)"DICARBOXYLIC"(W)"ACID"(W)"BIS"(W)"
```

```
                BIPHENYL"(W)"2"(W)"YLMETHYL"(W)"AMIDE")/BI)
             4 449734/BI
        389660 45/BI
        964506 6/BI
             0 449734-45-6/BI
                ((449734(W)45(W)6)/BI)
             1 544678/BI
        181577 73/BI
       1009273 1/BI
             0 544678-73-1/BI
                ((544678(W)73(W)1)/BI)
L5           0 ("PYRIDINE-2,4-DICARBOXYLIC ACID BIS(((BIPHENYL)-2-YLMETHYL)AMID
               E)"/BI OR 449734-45-6/BI OR 544678-73-1/BI)

=> file derwent
'DERWENT' IS NOT A VALID FILE NAME
SESSION CONTINUES IN FILE 'PCTFULL'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available.  If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

=> file uspat2 epfull
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     4.64      53.54

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                       ENTRY    SESSION
CA SUBSCRIBER PRICE                                     0.00      -1.50

FILE 'USPAT2' ENTERED AT 11:56:41 ON 25 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EPFULL' ENTERED AT 11:56:41 ON 25 APR 2006
COPYRIGHT (C) 2006 European Patent Office / FIZ Karlsruhe

=> s E1-E3
L6           2 ("PYRIDINE-2,4-DICARBOXYLIC ACID BIS(((BIPHENYL)-2-YLMETHYL)AMID
               E)"/BI OR 449734-45-6/BI OR 544678-73-1/BI)

=> d L6 1-2 ti abs bib

L6   ANSWER 1 OF 2  USPAT2 on STN
TI     Pyridine matrix metalloproteinase inhibitors
AB     Selective MMP-13 inhibitors are pyridine derivatives of the formula
       ##STR1##   or a pharmaceutically acceptable salt thereof,  wherein:
R.sup.1 and R.sup.2 independently are hydrogen, halo, hydroxy, C.sub.1-C.sub.6
       alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6
       alkynyl, NO.sub.2, NR.sup.4R.sup.5, CN, or CF.sub.3;
E is independently O or S;
A and B independently are OR.sup.4 or NR.sup.4R.sup.5;
R.sup.4 and R.sup.5 independently are H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6
       alkenyl, C.sub.2-C.sub.6 alkynyl, (CH.sub.2).sub.n aryl,
       (CH.sub.2).sub.n cycloalkyl, (CH.sub.2).sub.n heteroaryl, or R.sup.4 and
       R.sup.5 when taken together with the nitrogen to which they are attached
       complete a 3- to 8-membered ring containing carbon atoms and optionally
       containing a heteroatom selected from O, S, or NH, and optionally
       substituted or unsubstituted;
n is an integer of from 0 to 6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN     2004:268379  USPAT2
TI     Pyridine matrix metalloproteinase inhibitors
IN     Barvian, Nicole Chantel, Ann Arbor, MI, UNITED STATES
```

Connor, David Thomas, Ann Arbor, MI, UNITED STATES
Ortwine, Daniel Fred, Saline, MI, UNITED STATES
Patt, William Chester, Chelsea, MI, UNITED STATES
Wilson, Michael William, Ann Arbor, MI, UNITED STATES
PA Warner-Lambert Company, Morris Plains, NJ, UNITED STATES (U.S. corporation)
PI US 7015237 B2 20060321
AI US 2004-842863 20040510 (10)
RLI Division of Ser. No. US 2002-71073, filed on 8 Feb 2002, Pat. No. US 6881743
PRAI US 2001-268781P 20010214 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Morris, Patricia L.
LREP Purchase, Jr., Claude F., Crissey, Todd M., Ashbrook, Charles W.
CLMN Number of Claims: 5
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 1497
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L6 ANSWER 2 OF 2 USPAT2 on STN
TI Pyridine matrix metalloproteinase inhibitors
AB Selective MMP-13 inhibitors are pyridine derivatives of the formula ##STR1## or a pharmaceutically acceptable salt thereof,

wherein:
R.sup.1 and R.sup.2 independently are hydrogen, halo, hydroxy, C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, NO.sup.2, NR.sup.4R.sup.5, CN, or CF.sub.3,
E is independently O or S;
A and B independently are OR.sup.4 or NR.sup.4R.sup.5;
R.sup.4 and R.sup.5 independently are H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, (CH.sub.2).sub.n aryl, (CH.sub.2).sub.n cycloalkyl, (CH.sub.2).sub.n heteroaryl, or R.sup.4 and R.sup.5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted,
n is an integer of from 0 to 6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2002:288130 USPAT2
TI Pyridine matrix metalloproteinase inhibitors
IN Barvian, Nicole Chantel, Ann Arbor, MI, UNITED STATES
Connor, David Thomas, Ann Arbor, MI, UNITED STATES
O'Brien, Patrick Michael, Stockbridge, MI, UNITED STATES
Ortwine, Daniel Fred, Saline, MI, UNITED STATES
Patt, William Chester, Chelsea, MI, UNITED STATES
Shuler, Kevon Ray, Chelsea, MI, UNITED STATES
Wilson, Michael William, Ann Arbor, MI, UNITED STATES
PA Warner-Lambert Company, Morris Plains, NJ, UNITED STATES (U.S. corporation)
PI US 6881743 B2 20050419
AI US 2002-71073 20020208 (10)
PRAI US 2001-268781P 20010214 (60)
DT Utility
FS GRANTED
EXNAM Primary Examiner: Morris, Patricia L.
LREP Pfizer Inc., Ashbrook, Charles W., Purchase, Jr., Claude F.
CLMN Number of Claims: 13
ECL Exemplary Claim: 1
DRWN 0 Drawing Figure(s); 0 Drawing Page(s)
LN.CNT 1604

```
CAS INDEXING IS AVAILABLE FOR THIS PATENT.


=> file dpci
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         7.29      60.83

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -1.50

FILE 'DPCI' ENTERED AT 11:57:55 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE LAST UPDATED: 16 APR 2006       <20060416/UP>
PATENTS CITATION INDEX, COVERS 1973 TO DATE

>>>  LEARNING FILE LDPCI AVAILABLE  <<<

>>> PLEASE BE AWARE OF THE NEW IPC REFORM IN 2006, SEE
http://www.stn-international.de/stndatabases/details/ipc_reform.html  and
http://scientific.thomson.com/media/scpdf/ipcrdwpi.pdf <<<

=> s E1-E3
          6788 "PYRIDINE"/BI
        141300 "2"/BI
         93283 "4"/BI
          1918 "DICARBOXYLIC"/BI
        183896 "ACID"/BI
         14095 "BIS"/BI
           515 "BIPHENYL"/BI
        141300 "2"/BI
           119 "YLMETHYL"/BI
         12498 "AMIDE"/BI
             0 "PYRIDINE-2,4-DICARBOXYLIC ACID BIS(((BIPHENYL)-2-YLMETHYL)AMIDE
               )"/BI
                 (("PYRIDINE"(W)"2"(W)"4"(W)"DICARBOXYLIC"(W)"ACID"(W)"BIS"(W)"
                BIPHENYL"(W)"2"(W)"YLMETHYL"(W)"AMIDE")/BI)
             0 449734/BI
          1482 45/BI
         43962 6/BI
             0 449734-45-6/BI
                 ((449734(W)45(W)6)/BI)
             0 544678/BI
            58 73/BI
        183683 1/BI
             0 544678-73-1/BI
                 ((544678(W)73(W)1)/BI)
L7           0 ("PYRIDINE-2,4-DICARBOXYLIC ACID BIS(((BIPHENYL)-2-YLMETHYL)AMID
               E)"/BI OR 449734-45-6/BI OR 544678-73-1/BI)

=> file bioscience
FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS                                    SINCE FILE      TOTAL
                                                           ENTRY    SESSION
FULL ESTIMATED COST                                         1.60      62.43

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)              SINCE FILE      TOTAL
                                                           ENTRY    SESSION
CA SUBSCRIBER PRICE                                         0.00      -1.50

FILE 'ADISCTI' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Adis Data Information BV
```

FILE 'ADISINSIGHT' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Adis Data Information BV

FILE 'ADISNEWS' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Adis Data Information BV

FILE 'AGRICOLA' ENTERED AT 11:58:24 ON 25 APR 2006

FILE 'ANABSTR' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (c) 2006 THE ROYAL SOCIETY OF CHEMISTRY (RSC)

FILE 'ANTE' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'AQUALINE' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'AQUASCI' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT 2006 FAO (On behalf of the ASFA Advisory Board). All rights reserved.

FILE 'BIOENG' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'BIOSIS' ENTERED AT 11:58:24 ON 25 APR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHABS' ACCESS NOT AUTHORIZED

FILE 'BIOTECHDS' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'BIOTECHNO' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'CABA' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 CAB INTERNATIONAL (CABI)

FILE 'CAPLUS' ENTERED AT 11:58:24 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'CEABA-VTB' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (c) 2006 DECHEMA eV

FILE 'CIN' ENTERED AT 11:58:24 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

FILE 'CONFSCI' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'CROPB' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'CROPU' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'DDFB' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'DDFU' ACCESS NOT AUTHORIZED

FILE 'DGENE' ENTERED AT 11:58:24 ON 25 APR 2006

COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'DISSABS' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 ProQuest Information and Learning Company; All Rights Reserved.

FILE 'DRUGB' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'DRUGMONOG2' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 IMSWORLD Publications Ltd

FILE 'DRUGU' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'EMBAL' ENTERED AT 11:58:24 ON 25 APR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'EMBASE' ENTERED AT 11:58:24 ON 25 APR 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'ESBIOBASE' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Elsevier Science B.V., Amsterdam. All rights reserved.

FILE 'FOMAD' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Leatherhead Food Research Association

FILE 'FOREGE' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Leatherhead Food Research Association

FILE 'FROSTI' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Leatherhead Food Research Association

FILE 'FSTA' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 International Food Information Service

FILE 'GENBANK' ENTERED AT 11:58:24 ON 25 APR 2006

FILE 'HEALSAFE' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'IFIPAT' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 IFI CLAIMS(R) Patent Services (IFI)

FILE 'IMSDRUGNEWS' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 IMSWORLD Publications Ltd

FILE 'IMSPRODUCT' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 IMSWORLD Publications Ltd

FILE 'IMSRESEARCH' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 IMSWORLD Publications Ltd

FILE 'JICST-EPLUS' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Japan Science and Technology Agency (JST)

FILE 'KOSMET' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 International Federation of the Societies of Cosmetics Chemists

FILE 'LIFESCI' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'MEDLINE' ENTERED AT 11:58:24 ON 25 APR 2006

FILE 'NTIS' ENTERED AT 11:58:24 ON 25 APR 2006
Compiled and distributed by the NTIS, U.S. Department of Commerce.
It contains copyrighted material.
All rights reserved. (2006)

FILE 'NUTRACEUT' ENTERED AT 11:58:24 ON 25 APR 2006
Copyright 2006 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'OCEAN' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'PASCAL' ENTERED AT 11:58:24 ON 25 APR 2006
Any reproduction or dissemination in part or in full,
by means of any process and on any support whatsoever
is prohibited without the prior written agreement of INIST-CNRS.
COPYRIGHT (C) 2006 INIST-CNRS. All rights reserved.

FILE 'PCTGEN' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 WIPO

FILE 'PHAR' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Informa UK Ltd.

FILE 'PHARMAML' ENTERED AT 11:58:24 ON 25 APR 2006
Copyright 2006 (c) MARKETLETTER Publications Ltd. All rights reserved.

FILE 'PHIC' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Informa UK Ltd.

FILE 'PHIN' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Informa UK Ltd.

FILE 'PROMT' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Gale Group. All rights reserved.

FILE 'PROUSDDR' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Prous Science

FILE 'PS' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Thieme on STN

FILE 'RDISCLOSURE' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Kenneth Mason Publications Ltd.

FILE 'SCISEARCH' ENTERED AT 11:58:24 ON 25 APR 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'SYNTHLINE' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Prous Science

FILE 'TOXCENTER' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 ACS

FILE 'USPATFULL' ENTERED AT 11:58:24 ON 25 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPAT2' ENTERED AT 11:58:24 ON 25 APR 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'VETB' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'VETU' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

```
FILE 'WATER' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 Cambridge Scientific Abstracts (CSA)

FILE 'WPIDS' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPIFV' ENTERED AT 11:58:24 ON 25 APR 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'WPINDEX' ACCESS NOT AUTHORIZED

=> index E1-E3
'PYRIDINE-2,4' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):
ENTER A FILE NAME OR (IGNORE):ignore
'544678-73-1' IS NOT A VALID FILE NAME
ENTER A FILE NAME OR (IGNORE):ignore
AT LEAST TWO FILES ARE NEEDED FOR STNINDEX
SESSION CONTINUES IN THE PREVIOUS FILE ENVIRONMENT
To see a list of files and clusters that may be used in the INDEX
command, enter HELP FILE NAMES or HELP CLUSTER NAMES at an arrow
prompt.  Only the learning files and NBSFLUIDS may not be used in
STNINDEX.

=> focus E1-E3
'E1-E3' IS NOT VALID HERE
Only numbers and dashes (-) may be used to specify the answers to
be FOCUSed, for example, "FOCUS L2 1-10 13".
ENTER ANSWER NUMBERS OR TAGGED (?):
ENTER ANSWER NUMBERS OR TAGGED (?):
ENTER ANSWER NUMBERS OR TAGGED (?):1
PROCESSING COMPLETED FOR L6
L8             1 FOCUS L6 1

=> s E1-E3
  14 FILES SEARCHED...
  31 FILES SEARCHED...
  46 FILES SEARCHED...
  64 FILES SEARCHED...
L9           10 ("PYRIDINE-2,4-DICARBOXYLIC ACID BIS(((BIPHENYL)-2-YLMETHYL)AMID
                E)"/BI OR 449734-45-6/BI OR 544678-73-1/BI)

=> dup rem L9
DUPLICATE IS NOT AVAILABLE IN 'ADISINSIGHT, ADISNEWS, DGENE, DRUGMONOG2,
FOREGE, GENBANK, IMSPRODUCT, IMSRESEARCH, KOSMET, NUTRACEUT, PCTGEN, PHAR,
PHARMAML, PROUSDDR, PS, RDISCLOSURE, SYNTHLINE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L9
L10            6 DUP REM L9 (4 DUPLICATES REMOVED)

=> d L10 1-6 ti abs bib

L10  ANSWER 1 OF 6  USPATFULL on STN                        DUPLICATE 1
TI     Pyridine matrix metalloproteinase inhibitors
AB     Selective MMP-13 inhibitors are pyridine derivatives of the formula
       ##STR1##

       or a pharmaceutically acceptable salt thereof,

       wherein:

       R.sup.1 and R.sup.2 independently are hydrogen, halo, hydroxy,
       C.sub.1-C.sub.6 alkyl, C.sub.1-C.sub.6 alkoxy, C.sub.2-C.sub.6 alkenyl,
       C.sub.2-C.sub.6 alkynyl, N0.sub.2, NR.sup.4R.sup.5, CN, or CF.sub.3;
```

E is independently O or S;

A and B independently are OR.sup.4 or NR.sup.4R.sup.5;

R.sup.4 and R.sup.5 independently are H, C.sub.1-C.sub.6 alkyl, C.sub.2-C.sub.6 alkenyl, C.sub.2-C.sub.6 alkynyl, (CH.sub.2).sub.n aryl, (CH.sub.2).sub.n cycloalkyl, (CH.sub.2).sub.n heteroaryl, or R.sup.4 and R.sup.5 when taken together with the nitrogen to which they are attached complete a 3- to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted;

n is an integer of from 0 to 6.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:268379 USPATFULL
TI Pyridine matrix metalloproteinase inhibitors
IN Barvian, Nicole Chantel, Ann Arbor, MI, UNITED STATES
Connor, David Thomas, Ann Arbor, MI, UNITED STATES
O'Brien, Patrick Michael, Stockbridge, MI, UNITED STATES
Ortwine, Daniel Fred, Saline, MI, UNITED STATES
Patt, William Chester, Chelsea, MI, UNITED STATES
Wilson, Michael William, Ann Arbor, MI, UNITED STATES
PI US 2004209922 A1 20041021
US 7015237 B2 20060321
AI US 2004-842863 A1 20040510 (10)
RLI Division of Ser. No. US 2002-71073, filed on 8 Feb 2002, PENDING
PRAI US 2001-268781P 20010214 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 13
ECL Exemplary Claim: CLM-001-9
DRWN No Drawings
LN.CNT 1657
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 2 OF 6 USPATFULL on STN
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
AB This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with a selective inhibitor of COX-2, or a pharmaceutically acceptable salt thereof, that is not celecoxib or valdecoxib, and a pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a combination comprising an NSAID, or a pharmaceutically acceptable salt thereof, and an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof, and a

pharmaceutically acceptable carrier, diluent, or excipient. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-1 or cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with an NSAID, or a pharmaceutically acceptable salt thereof. The invention combinations may also be further combined with other pharmaceutical agents depending on the disease being treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:25212 USPATFULL
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with a selective inhibitor of cyclooxygenase-2 that is not celecoxib or valdecoxib
IN Roark, William Howard, Ann Arbor, MI, UNITED STATES
PI US 2004019054 A1 20040129
AI US 2003-619769 A1 20030715 (10)
PRAI US 2002-396785P 20020717 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 9
ECL Exemplary Claim: 1
DRWN No Drawings
LN.CNT 8368
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 3 OF 6 USPATFULL on STN
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
AB This invention provides a combination, comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a method of treating a disease that is responsive to inhibition of MMP-13 and cyclooxygenase-2, comprising administering to a patient suffering from such a disease the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof. This invention also provides a pharmaceutical composition, comprising the invention combination comprising an allosteric carboxylic inhibitor of MMP-13, or a pharmaceutically acceptable salt thereof, with celecoxib, or a pharmaceutically acceptable salt thereof, or valdecoxib, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.

The invention combination may also be further combined with other pharmaceutical agents depending on the disease being treated.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.
AN 2004:25211 USPATFULL
TI Combination of an allosteric carboxylic inhibitor of matrix metalloproteinase-13 with celecoxib or valdecoxib
IN Roark, William Howard, Ann Arbor, MI, UNITED STATES
PI US 2004019053 A1 20040129
AI US 2003-619662 A1 20030715 (10)
PRAI US 2002-396903P 20020717 (60)
DT Utility
FS APPLICATION
LREP WARNER-LAMBERT COMPANY, 2800 PLYMOUTH RD, ANN ARBOR, MI, 48105
CLMN Number of Claims: 9
ECL Exemplary Claim: 1

DRWN No Drawings
LN.CNT 8040
CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L10 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2,4-pyridinedicarboxamides and 4,6-pyrimidinedicarboxamides as inhibitors of collagenase (MMP 13)
GI



I

AB Title compds. [I; A = CH, N; R1-R3 = H, halo, (halogenated) alkyl, alkoxy, OH, CO2R4, cyano, NR5R6, etc.; R4 = H, alkyl; R5, R6 = H, alkyl, alkylcarbonyl, etc.; or R1R2, R2R3 = 5-6 membered (aromatic) (saturated) (hetero)cyclyl], were prepd for the treatment of degenerative joint diseases. Thus, 4,6-pyrimidinedicarboxylic acid in SOCl2 was stirred for 2 h at 85° followed by addition of CH2Cl2 at room temperature and Et3N at 0°. The reaction mixture was further stirred with 3-chloro-4-fluorobenzylamine for 15 min to give 40% N,N-bis(3-chloro-4-fluorobenzyl)pyrimidine-4,6-dicarboxamide. The latter inhibited collagenase 3 (MMP 13) with IC50 = 23 nM.
AN 2003:467290 CAPLUS
DN 139:53028
TI Preparation of 2,4-pyridinedicarboxamides and 4,6-pyrimidinedicarboxamides as inhibitors of collagenase (MMP 13)
IN Habermann, Joerg; Weithmann, Klaus-Ulrich; Kogler, Herbert; Kirsch, Reinhard; Wehner, Volkmar
PA Aventis Pharma Deutschland G.m.b.H., Germany
SO Ger. Offen., 20 pp.
CODEN: GWXXBX
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 10160357	A1	20030618	DE 2001-10160357	20011208
	CA 2469625	AA	20030619	CA 2002-2469625	20021125
	WO 2003049738	A1	20030619	WO 2002-EP13240	20021125
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002358535	A1	20030623	AU 2002-358535	20021125
	EP 1455790	A1	20040915	EP 2002-792799	20021125
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	JP 2005513049	T2	20050512	JP 2003-550787	20021125
	US 2003229103	A1	20031211	US 2002-65994	20021209
	US 6933298	B2	20050823		
PRAI	DE 2001-10160357	A	20011208		
	US 2002-358887P	P	20020222		

WO 2002-EP13240 W 20021125
OS MARPAT 139:53028

L10 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2006 ACS on STN DUPLICATE 2
TI Preparation of pyridinedicarboxamide and -dicarboxylic acid derivatives as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses
GI



I

AB Selective MMP-13 inhibitors are pyridine derivs. (I; e.g. pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)) or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are H, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H, C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the N to which they are attached complete a 3- to 8-membered ring containing C atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted; n is 0 to 6. Although I and other Markush structures in the patent show 2,4- derivs., many specific 3,5- derivs. are included in the claims and examples. Combinatorial and non-combinatorial methods were used to prepare numerous claimed compds. and characterization data is reported for about 90 compds. IC50 values for various claimed compds. show the selectivity towards MMP-13 vs. MMP-1 and MMP-3 and the potent MMP-13 inhibitory activity (e.g. 0.033 μM for pyridine-2,4-dicarboxylic acid bis[((1,3-benzodioxol-5-yl)methyl)amide]).
AN 2002:637657 CAPLUS
DN 137:185420
TI Preparation of pyridinedicarboxamide and -dicarboxylic acid derivatives as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses
IN Barvian, Nicole Chantel; Connor, David Thomas; O'brien, Patrick Michael; Ortwine, Daniel Fred; Patt, William Chester; Shuler, Kevon Ray; Wilson, Michael William
PA Warner-Lambert Company, USA
SO PCT Int. Appl., 68 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002064568	A1	20020822	WO 2002-IB345	20020204
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434982	AA	20020822	CA 2002-2434982	20020204
EP 1362033	A1	20031119	EP 2002-716263	20020204

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

	EE 200300391	A	20031215	EE 2003-391	20020204
	BR 2002007863	A	20040427	BR 2002-7863	20020204
	JP 2004529878	T2	20040930	JP 2002-564501	20020204
	CN 1537101	A	20041013	CN 2002-804945	20020204
	US 2002161000	A1	20021031	US 2002-71073	20020208
	US 6881743	B2	20050419		
	ZA 2003006041	A	20041105	ZA 2003-6041	20030805
	NO 2003003570	A	20030812	NO 2003-3570	20030812
	BG 108089	A	20050131	BG 2003-108089	20030813
	US 2004209922	A1	20041021	US 2004-842863	20040510
	US 7015237	B2	20060321		
PRAI	US 2001-268781P	P	20010214		
	WO 2002-IB345	W	20020204		
	US 2002-71073	A3	20020208		

OS MARPAT 137:185420
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 6 OF 6 IFIPAT COPYRIGHT 2006 IFI on STN DUPLICATE 3
TI PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS; TREATING DISEASES RESULTING FROM TISSUE BREAKDOWN SUCH AS HEART DISEASE, MULTIPLE SCLEROSIS, OSTEO- AND RHEUMATOID ARTHRITIS, ATHEROSCLEROSIS, AND OSTEOPOROSIS
AB Selective MMP-13 inhibitors are pyridine derivatives of the formula

D R A W I N G

or a pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently are hydrogen, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6 alkynyl, NO2, NR4R5, CN, or CF3, E is independently O or S; A and B independently are OR4 or NR4R5; R4 and R5 independently are H. C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl, (CH2)n heteroaryl, or R4 and R5 when taken together with the nitrogen to which they are attached complete a 3 to 8-membered ring containing carbon atoms and optionally containing a heteroatom selected from O, S, or NH, and optionally substituted or unsubstituted, n is an integer of from 0 to 6.

CLMN 35
AN 10217293 IFIPAT;IFIUDB;IFICDB
TI PYRIDINE MATRIX METALLOPROTEINASE INHIBITORS; TREATING DISEASES RESULTING FROM TISSUE BREAKDOWN SUCH AS HEART DISEASE, MULTIPLE SCLEROSIS, OSTEO- AND RHEUMATOID ARTHRITIS, ATHEROSCLEROSIS, AND OSTEOPOROSIS
INF Barvian; Nicole Chantel, Ann Arbor, MI, US
Connor; David Thomas, Ann Arbor, MI, US
O'Brien; Patrick Michael, Stockbridge, MI, US
Ortwine; Daniel Fred, Saline, MI, US
Patt; William Chester, Chelsea, MI, US
Shuler; Kevon Ray, Chelsea, MI, US
Wilson; Michael William, Ann Arbor, MI, US
IN Barvian Nicole Chantel; Connor David Thomas; O'Brien Patrick Michael; Ortwine Daniel Fred; Patt William Chester; Shuler Kevon Ray; Wilson Michael William
PAF Unassigned
PA Unassigned Or Assigned To Individual (68000)
PPA Warner-Lambert Co (Probable)
AG Claude F. Purchase, Jr. Warner-Lambert Company, 2800 Plymouth Road, Ann Arbor, MI 48105, US
PI US 2002161000 A1 20021031
AI US 2002-71073 20020208
PRAI US 2001-268781P 20010214 (Provisional)
FI US 2002161000 20021031
US 6881743 20050419
DT Utility; Patent Application - First Publication
FS CHEMICAL

```
      APPLICATION
CLMN  35


=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                     178.83     241.26

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -1.50      -3.00

STN INTERNATIONAL LOGOFF AT 12:01:34 ON 25 APR 2006
```

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTAEXO1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS	1		Web Page URLs for STN Seminar Schedule - N. America
NEWS	2		"Ask CAS" for self-help around the clock
NEWS	3	DEC 23	New IPC8 SEARCH, DISPLAY, and SELECT fields in USPATFULL/ USPAT2
NEWS	4	JAN 13	IPC 8 searching in IFIPAT, IFIUDB, and IFICDB
NEWS	5	JAN 13	New IPC 8 SEARCH, DISPLAY, and SELECT enhancements added to INPADOC
NEWS	6	JAN 17	Pre-1988 INPI data added to MARPAT
NEWS	7	JAN 17	IPC 8 in the WPI family of databases including WPIFV
NEWS	8	JAN 30	Saved answer limit increased
NEWS	9	FEB 21	STN AnaVist, Version 1.1, lets you share your STN AnaVist visualization results
NEWS	10	FEB 22	The IPC thesaurus added to additional patent databases on STN
NEWS	11	FEB 22	Updates in EPFULL; IPC 8 enhancements added
NEWS	12	FEB 27	New STN AnaVist pricing effective March 1, 2006
NEWS	13	FEB 28	MEDLINE/LMEDLINE reload improves functionality
NEWS	14	FEB 28	TOXCENTER reloaded with enhancements
NEWS	15	FEB 28	REGISTRY/ZREGISTRY enhanced with more experimental spectral property data
NEWS	16	MAR 01	INSPEC reloaded and enhanced
NEWS	17	MAR 03	Updates in PATDPA; addition of IPC 8 data without attributes
NEWS	18	MAR 08	X.25 communication option no longer available after June 2006
NEWS	19	MAR 22	EMBASE is now updated on a daily basis
NEWS	20	APR 03	New IPC 8 fields and IPC thesaurus added to PATDPAFULL
NEWS	21	APR 03	Bibliographic data updates resume; new IPC 8 fields and IPC thesaurus added in PCTFULL
NEWS	22	APR 04	STN AnaVist $500 visualization usage credit offered
NEWS	23	APR 12	LINSPEC, learning database for INSPEC, reloaded and enhanced
NEWS	24	APR 12	Improved structure highlighting in FQHIT and QHIT display in MARPAT
NEWS	25	APR 12	Derwent World Patents Index to be reloaded and enhanced during second quarter; strategies may be affected

NEWS EXPRESS FEBRUARY 15 CURRENT VERSION FOR WINDOWS IS V8.01a,
CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),
AND CURRENT DISCOVER FILE IS DATED 19 DECEMBER 2005.
V8.0 AND V8.01 USERS CAN OBTAIN THE UPGRADE TO V8.01a AT
http://download.cas.org/express/v8.0-Discover/

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items
NEWS IPC8 For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation

of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 15:59:34 ON 25 APR 2006

=> file caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 15:59:56 ON 25 APR 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 25 Apr 2006 VOL 144 ISS 18
FILE LAST UPDATED: 24 Apr 2006 (20060424/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

```
=> s pyridinedicarbox? op pyridinecarboxy?
          5068 PYRIDINEDICARBOX?
         14670 OP
          5743 PYRIDINECARBOXY?
L1           0 PYRIDINEDICARBOX? OP PYRIDINECARBOXY?
                 (PYRIDINEDICARBOX?(W)OP(W)PYRIDINECARBOXY?)

=> s pyridinedicarbox? or pyridinecarboxy?
          5068 PYRIDINEDICARBOX?
          5743 PYRIDINECARBOXY?
L2       10247 PYRIDINEDICARBOX? OR PYRIDINECARBOXY?

=> s L2 and (solubilizing(w)agent)
         10403 SOLUBILIZING
        775866 AGENT
          1385 SOLUBILIZING(W)AGENT
L3           3 L2 AND (SOLUBILIZING(W)AGENT)

=> d L3 1-3 ti abs bib

L3   ANSWER 1 OF 3  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Pharmaceutical compositions containing polymer for enhanced drug
     concentrations
AB   A drug in a solubility-improved form is combined with a concentration-enhancing
     polymer, i.e., a cellulosic or non-cellulosic polymer, in a sufficient
     amount so that the combination provides substantially enhanced drug
concentration
     in a use environment,, such as digestive tract, s.c. space, vagina, lung,
     blood vessels, and muscle relative to a control comprising the same amount
```

of the same solubility-improved form of drug without the concentration-enhancing polymer. For example, the solubility of sertraline-HCl was increased in presence of citric acid, giving a solubility-improvement factor of 9.3. Thus, citric acid is an excellent **solubilizing agent** for sertraline-HCl. A solution was prepared containing 1000 μg/mL sertraline-HCl, 500 μg/mL citric acid, and 1000 μg/mL hydroxypropyl Me cellulose acetate succinate (HPMCAS) in phosphate buffer. (pH 7.9). Addition of the concentration-enhancing polymer HPMCAS resulted in a maximum concentration that was 1.7-fold that of control containing no polymer.

AN 2001:489208 CAPLUS
DN 135:97443
TI Pharmaceutical compositions containing polymer for enhanced drug concentrations
IN Babcock, Walter Christian; Curatolo, William John; Friesen, Dwayne Thomas; Lorenz, Douglas Alan; Nightingale, James Alan Schriver; Shanker, Ravi Mysore
PA Pfizer Products Inc., USA
SO PCT Int. Appl., 85 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2001047495	A1	20010705	WO 2000-IB1787	20001201
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2395331	AA	20010705	CA 2000-2395331	20001201
BR 2000016555	A	20020917	BR 2000-16555	20001201
EP 1239835	A1	20020918	EP 2000-976217	20001201
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
TR 200201617	T2	20021021	TR 2002-200201617	20001201
JP 2003518485	T2	20030610	JP 2001-548090	20001201
EE 200200357	A	20031015	EE 2002-357	20001201
AU 784340	B2	20060316	AU 2001-14091	20001201
US 2002006443	A1	20020117	US 2000-742785	20001220
BG 106764	A	20030331	BG 2002-106764	20020531
ZA 2002004962	A	20030929	ZA 2002-4962	20020620
NO 2002002998	A	20020815	NO 2002-2998	20020621
PRAI US 1999-171841P	P	19991223		
WO 2000-IB1787	W	20001201		

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI Chelation extraction of lead from soil using pyridine-2,6-dicarboxylic acid
AB Pyridine-2,6-dicarboxylic acid (PDA) was used as a Pb-complexing agent. Batch testing involving PDA extraction of Pb from spiked soils showed PDA to be an effective Pb **solubilizing agent** across a wide pH range. Pb extraction efficiency was independent of the total carbonate concentration, competing cations, or the soil aging period. PDA compared favorably with EDTA as a Pb-complexing agent, while behaving more desirably than EDTA in releasing the extracted Pb. PDA was effectively reclaimed and reused in 4

successive extraction procedures, achieving in each run a Pb extraction efficiency
that exceeded 80% recovery of the total Pb present in the spiked soil. In recovery procedures, the complex solution was elevated to a pH of .apprx.10, separating the Pb as a hydroxide precipitate, and allowing for virtually complete
recovery of the PDA in solution
AN 1995:414081 CAPLUS
DN 122:195965
TI Chelation extraction of lead from soil using pyridine-2,6-dicarboxylic acid
AU Macauley, Edward; Hong, Andrew
CS Department of Civil Engineering, University of Utah, Salt Lake City, UT, 84112, USA
SO Journal of Hazardous Materials (1995), 40(3), 257-70
CODEN: JHMAD9; ISSN: 0304-3894
PB Elsevier
DT Journal
LA English

L3 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2006 ACS on STN
TI Solubilizing agents. VIII. Pharmaceutical application of acid amides as solubilizing agents
AB cf. CA 55, 10440c. Ten acid amides were examined for their use as a solubilization agent. The majority of them have very small toxicity. Solubilization effects of these substances on sparingly soluble pharmaceutical prepns. and food additives showed that they can be used for such practical purposes.
AN 1962:13216 CAPLUS
DN 56:13216
OREF 56:2515e-f
TI Solubilizing agents. VIII. Pharmaceutical application of acid amides as solubilizing agents
AU Samejima, Masayoshi
CS Tanabe Siyaku Co., Osaka
SO Yakugaku Zasshi (1961), 81, 1208
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Unavailable

=> s pyridinedicarboxamide or pyridinecarboxamide
309 PYRIDINEDICARBOXAMIDE
1547 PYRIDINECARBOXAMIDE
L4 1836 PYRIDINEDICARBOXAMIDE OR PYRIDINECARBOXAMIDE

=> s L4 and (solubilizing(w)agent)
10403 SOLUBILIZING
775866 AGENT
1385 SOLUBILIZING(W)AGENT
L5 1 L4 AND (SOLUBILIZING(W)AGENT)

=> d l5 ti abs bib

L5 ANSWER 1 OF 1 CAPLUS COPYRIGHT 2006 ACS on STN
TI Solubilizing agents. VIII. Pharmaceutical application of acid amides as solubilizing agents
AB cf. CA 55, 10440c. Ten acid amides were examined for their use as a solubilization agent. The majority of them have very small toxicity. Solubilization effects of these substances on sparingly soluble pharmaceutical prepns. and food additives showed that they can be used for such practical purposes.
AN 1962:13216 CAPLUS
DN 56:13216
OREF 56:2515e-f

TI Solubilizing agents. VIII. Pharmaceutical application of acid amides as solubilizing agents
AU Samejima, Masayoshi
CS Tanabe Siyaku Co., Osaka
SO Yakugaku Zasshi (1961), 81, 1208
CODEN: YKKZAJ; ISSN: 0031-6903
DT Journal
LA Unavailable

=> s L4 and arthritis
40833 ARTHRITIS
L6 42 L4 AND ARTHRITIS

=> d L6 1-46 ti

L6 ANSWER 1 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Adamantyl derivatives as P2X7 receptor antagonists, their preparation, pharmaceutical compositions, and use in therapy

L6 ANSWER 2 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pyridine derivatives, particularly 6-amino-5-phenylpyridine-2-carboxylic acid amides, with activity as sodium channel modulators, useful for the treatment of pain, and their preparation, pharmaceutical compositions, and use

L6 ANSWER 3 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of nitrogen-heteroaryl-containing protein kinase modulators for use against cancer and other diseases

L6 ANSWER 4 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of triazolyl arylbenzamides as inhibitors of cytokines

L6 ANSWER 5 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of pyridine derivatives as akt kinase inhibitors

L6 ANSWER 6 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2-pyridinecarboxamides as kinase inhibitors

L6 ANSWER 7 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of amido-substituted indazoles as Rho-kinase inhibitors

L6 ANSWER 8 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of benzyl ether amine compounds useful as CCR-5 antagonists

L6 ANSWER 9 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of aminofurazanyl imidazopyridines as Rho kinase inhibitors

L6 ANSWER 10 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Fluoro substituted omega-carboxyaryl diphenyl urea for treatment of raf, VEGFR, PDGFR, p38 and flt-3 kinase-mediated diseases

L6 ANSWER 11 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of pyrimidinecarboxamides, pyrimidinylcarbamates and related compounds as inhibitors of T cell activation for the treatment of inflammatory diseases

L6 ANSWER 12 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI A preparation of (thiopyranyloxy)**pyridinecarboxamide** derivatives, useful as TNF-α and PDE4 inhibitors

L6 ANSWER 13 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI A preparation of amphiphilic pyridinium compounds, useful for suppression of IL-8 secretion

L6 ANSWER 14 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of imidazo-fused oxazolo[4,5-b]pyridine and imidazo-fused thiazolo[4,5-b]pyridine based tricyclic compounds as IKK kinase inhibitors for treating inflammation and immune disorders

L6 ANSWER 15 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI A pharmaceutical composition comprising adamantane derivative P2X7 antagonists and sulfasalazine

L6 ANSWER 16 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2-anilino-4-(imidazol-5-yl)pyrimidine derivatives and their use as cdk (cdk2) kinase inhibitors

L6 ANSWER 17 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of bicyclic (hetero)aryl- and pyridine-containing diaryl ureas as Raf kinase and angiogenesis inhibitors useful in the treatment of cancer and other disorders

L6 ANSWER 18 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2-oxo-1,3,5-perhydrotriazapine derivatives for treatment of hyper-proliferative, angiogenesis, and inflammatory disorders

L6 ANSWER 19 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of compounds having 4-pyridylalkylthio group as inhibitors of angiogenesis and vascular permeability

L6 ANSWER 20 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of indazole derivatives as JNK enzyme inhibitors

L6 ANSWER 21 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of (pyridyl)(phenylpyridyl)pyrazoles as inhibitors of the transforming growth factor β

L6 ANSWER 22 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2-phenylpyridin-4-yl heterocycles as selective activin-like kinase-5 inhibitors useful against fibrosis and other disorders

L6 ANSWER 23 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of aminothiazoles as inhibitors of the transforming growth factor-beta (TGF-β) signalling pathway

L6 ANSWER 24 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of aryl ureas with angiogenesis inhibiting activity

L6 ANSWER 25 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 2,4-pyridinedicarboxamides and 4,6-pyrimidinedicarboxamides as inhibitors of collagenase (MMP 13)

L6 ANSWER 26 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of isoindoles as Factor Xa inhibitors

L6 ANSWER 27 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties

L6 ANSWER 28 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties

L6 ANSWER 29 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of 3-(azahetero)aryl-1H-pyrazolo[3,4-d]pyrimidin-3-amines as protein kinase inhibitors with antiangiogenic properties

L6 ANSWER 30 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of benzimidazol derivatives as modulators of chemokine

receptors

L6 ANSWER 31 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of **pyridinedicarboxamide** and -dicarboxylic acid derivatives as selective MMP-13 matrix metalloproteinase inhibitors with therapeutic uses

L6 ANSWER 32 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of carbamoyl-substituted pyridinyl aryl ether derivatives as inhibitors of phosphodiesterase IV isozymes

L6 ANSWER 33 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of novel N-substituted-γ,γ-trisubstituted lactam derivatives as matrix metalloproteinase inhibitors

L6 ANSWER 34 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Heteroaryl ureas containing nitrogen hetero-atoms as p38 kinase inhibitors

L6 ANSWER 35 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of cyclic amine derivatives for inhibition of the action of chemokines such as MIP-1α and/or MCP-1 on target cells

L6 ANSWER 36 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of Furanoisoquinoline derivatives as phosphodiesterase IV inhibitors

L6 ANSWER 37 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of arylalkanoylpyridazines for treatment of osteoporosis, tumors, arteriosclerosis, rheumatoid **arthritis**, multiple sclerosis, diabetes mellitus, ulcerative colitis and AIDS

L6 ANSWER 38 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of heterocyclic glycyl β-alanine derivatives as vitronectin antagonists

L6 ANSWER 39 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI 1,2-Substituted imidazolyl compounds for the treatment of inflammation

L6 ANSWER 40 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Dietary supplement for pain relief

L6 ANSWER 41 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Heteroaryl-Fused 2-Phenylisothiazolone Inhibitors of Cartilage Breakdown

L6 ANSWER 42 OF 42 CAPLUS COPYRIGHT 2006 ACS on STN
TI Transformations in the pyridine series. A simple preparation of 3-methyl-4-phenylpyridine and corresponding 2-carboxamides

=> s L6 anf py<2002
MISSING OPERATOR L6 ANF
The search profile that was entered contains terms or
nested terms that are not separated by a logical operator.

=> s L6 and py<2002
21808456 PY<2002
L7 7 L6 AND PY<2002

=> d L7 1-7 ti abs bib

L7 ANSWER 1 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Preparation of Furanoisoquinoline derivatives as phosphodiesterase IV inhibitors
GI



I

AB Title compds. [I; R1 = C6H5, 4-HOC6H4, 1-naphthyl, 4-CH3OC6H4, 2-CH3OC6H4, 4-NH2C6H4, 4-C6H5C6H4, 4-BrC6H4, CH3, C6H5CO, 3-CH3SCH2CONHC6H4, 3-CH3OCOC6H4, 3-NH2C(CH3)2CONHC6H4, 3-furyl, 3-HOOCC6H4, 2-chloro-4-pyridyl, 3-CH3CH2OCOC6H4, 4-pyridylethylaminocarbonyl; R2 = CH3, CH2Br, CH3CH2, H, CH3COO; R3 = CH3, H; R2R3 = (CH2)5; R4 = H, CH2N(CH3)2, CH2SC6H5, CH2C(:CH2)CH3, CH2NHCOCH3, CH3OCH2, CH2OH, CH2F, CH2COOH, CH2CN; R5 = Cl, OCH3, CON(CH3)2, CH3O, H, CH3CH2O, NH2, CHONH, CH3SO2NH, NH2CONH, CH3CH2S, CH3; R6 = CH3, H, CH3CH; R7 = CH3, H, CH3CH2; R6R7 = (CH2)5; R8 = H, CH3; R9 = H, CH3; Y = CH2, CHOH, C:O, C(CH3)2; X = electron pair, O, S; n = 0, 1] and salts are prepared as phosphodiesterase IV inhibitors. Title compds. are useful as preventives and remedies for diseases caused by inflammation, for example, bronchial asthma, chronic obstructive pulmonary disease (COPD), rheumatoid **arthritis**, autoimmune disease and diabetes. Thus, the title compound I (R6 = CH3; R7 = CH3; R2 = CH3; R3 = CH3; X = O; R5 = CH3; n = 0; R9 = H; R8 = H; R1 = 3-CH3S:OCH2CONHC6H4) was prepared and biol. tested.

AN 2001:713354 CAPLUS
DN 135:272895

TI Preparation of Furanoisoquinoline derivatives as phosphodiesterase IV inhibitors

IN Kawano, Yasuhiko; Matsumoto, Tatsumi; Uchikawa, Osamu; Fujii, Nobuhiro; Tarui, Naoki
PA Takeda Chemical Industries, Ltd., USA

SO PCT Int. Appl., 620 pp.
CODEN: PIXXD2
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2001070746	A1	20010927	WO 2001-JP2277	20010322 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2404226	AA	20010927	CA 2001-2404226	20010322 <--
	AU 2001039550	A5	20011003	AU 2001-39550	20010322 <--
	EP 1270577	A1	20030102	EP 2001-914191	20010322
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	JP 2001335579	A2	20011204	JP 2001-84210	20010323 <--
	US 2004092582	A1	20040513	US 2002-239439	20020920
	US 6924292	B2	20050802		
PRAI	JP 2000-87121	A	20000323		
	WO 2001-JP2277	W	20010322		

OS CASREACT 135:272895; MARPAT 135:272895
RE.CNT 11 THERE ARE 11 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 2 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Use of arylalkanoylpyridazines for treatment of osteoporosis, tumors, arteriosclerosis, rheumatoid **arthritis**, multiple sclerosis, diabetes mellitus, ulcerative colitis and AIDS
GI



I

AB The use of 1-acyl-3-aryl-1,4,5,6-tetrahydropyridazines I (B = A, OA, NH2, NHA, NHAA'; A,A' = C1-10-alkyl, fluoro-C1-10-alkyl, chloro-C1-10-alkyl, (substituted) heterocyclyl; Q = absent, C1-6-alkylene; R1, R2 = OH, OR5, SR5, SOR5, SO2R5, halo, NO2, NH2, NHR5, NR5R6, or R1R2 = OCH2O; R5, R6 = alkyl, C3-7-cycloalkyl, C4-8-methylenecycloalkyl, C2-8-alkenylene) is claimed for producing a medicament for treating osteoporosis, tumors, arteriosclerosis, rheumatoid **arthritis**, multiple sclerosis, diabetes mellitus, ulcerative colitis and AIDS. Thus, 4-[(nicotinoyl)amino]benzoyl chloride was added to a mixture of potassium tert-butylate and 3-(3,4-dimethoxyphenyl)-1,4,5,6-tetrahydropyridazine in THF to give N-[4-[[3-(3,4-dimethoxyphenyl)-5,6-dihydro-1(4H)-pyridazinyl]carbonyl]phenyl]-3-**pyridinecarboxamide** hydrochloride. The pharmacol. activity of the claimed compds. was not shown.
AN 2000:725445 CAPLUS
DN 133:301117
TI Use of arylalkanoylpyridazines for treatment of osteoporosis, tumors, arteriosclerosis, rheumatoid **arthritis**, multiple sclerosis, diabetes mellitus, ulcerative colitis and AIDS
IN Rochus, Jonas; Wolf, Michael; Beier, Norbert; Kluxen, Franz-Werner; Fittschen, Claus
PA Merck Patent G.m.b.H., Germany
SO PCT Int. Appl., 34 pp.
CODEN: PIXXD2
DT Patent
LA German
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000059484	A2	20001012	WO 2000-EP2280	20000315 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	DE 19915364	A1	20001012	DE 1999-19915364	19990406 <--
	CA 2367051	AA	20001012	CA 2000-2367051	20000315 <--
	EP 1143944	A2	20011017	EP 2000-916949	20000315 <--
	EP 1143944	A3	20020911		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO

	BR 2000009549	A	20020326	BR 2000-9549	20000315
	JP 2002541095	T2	20021203	JP 2000-609048	20000315
	NO 2001004845	A	20011005	NO 2001-4845	20011005 <--
	ZA 2001009120	A	20031113	ZA 2001-9120	20011105
PRAI	DE 1999-19915364	A	19990406		
	WO 2000-EP2280	W	20000315		

OS MARPAT 133:301117

L7 ANSWER 3 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN

TI Preparation of heterocyclic glycyl β-alanine derivatives as vitronectin antagonists

AB Tile compds. A(CY3Z3)t-Het-CO-V-(CYZ)n-CONR11CHR1(CH2)pCOR [Het = (un)substituted 5-8 membered monocyclic heterocyclic ring containing 1-4 heteroatoms selected from O, N, or S, optionally unsatd. and linked to (CY3Z3)t and CO at the 1- and 3-positions; A = NR5C(:Y1)NR7R8, NR5C(:NR7)Y2, or N:C(NR2R5)(NR7R8), where Y1 = NR2, O, S; R2, R7, R8 = H, alkyl, aryl, amino, etc. or R2 and R8 taken together form an (un)substituted dinitrogen heterocycle; R5 = H, alkyl, alkenyl, alkynyl, benzyl, phenethyl; and Y2 = alkyl, cycloalkyl, bicycloalkyl, aryl, etc.; V = NR6, where R6 = H, alkyl, cycloalkyl, aralkyl, aryl, monocyclic heterocyclyl or R6 together with Y forms a mono-nitrogen-containing ring; Y, Y3, Z, Z3 = H, alkyl, aryl, cycloalkyl or Y and Z together or Y3 and Z3 together form cycloalkyl; n = 1-3; t = 0-2; p = 0-3; R = X-R3, where X = O, S, or NR4 and R3 and R4 = H, alkyl, sugars, steroids, etc.; R1 = H, alkyl, alkenyl, alkynyl, aryl, etc.] or their pharmaceutically acceptable salts were prepared as vitronectin antagonists. Thus, 5-[(aminoiminomethyl)amino]-N-[2-[[2-carboxy-1-(3-bromo-5-chloro-2-hydroxyphenyl)ethyl]amino]-2-oxoethyl]-3-**pyridinecarboxamide** bis(trifluoroacetate) was prepared and showed IC50 = 1.58 nM for inhibition of human vitronectin receptor (αvβ3).

AN 1999:672798 CAPLUS

DN 131:299691

TI Preparation of heterocyclic glycyl β-alanine derivatives as vitronectin antagonists

IN Chandrakumar, Nizal Samuel; Desai, Bipinchandra Nanubhai; Devadas, Balekudru; Huff, Renee; Khanna, Ish K.; Rao, Shashidhar N.; Rico, Joseph G.; Rogers, Thomas E.; Ruminski, Peter G.; Russell, Mark Andrew; Yu, Yi; Gasiecki, Alan Frank; Malecha, James W.; Miyashiro, Julie M.

PA G.D. Searle and Co., USA

SO PCT Int. Appl., 269 pp.
CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9952896	A1	19991021	WO 1999-US4297	19990409 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	US 6689754	B1	20040210	US 1999-289140	19990408
	CA 2326665	AA	19991021	CA 1999-2326665	19990409 <--
	AU 9934499	A1	19991101	AU 1999-34499	19990409 <--
	AU 765294	B2	20030911		
	EP 1070060	A1	20010124	EP 1999-916119	19990409 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE, FI				
	BR 9910119	A	20011009	BR 1999-10119	19990409 <--
	JP 2002511462	T2	20020416	JP 2000-543454	19990409

	RU 2215746	C2	20031110	RU 2000-128033	19990409
	NZ 507292	A	20031219	NZ 1999-507292	19990409
	NO 2000005084	A	20001127	NO 2000-5084	20001009 <--
	US 2004127477	A1	20040701	US 2003-718328	20031120
PRAI	US 1998-81394P	P	19980410		
	US 1999-289140	A3	19990408		
	WO 1999-US4297	W	19990409		

OS MARPAT 131:299691
RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L7 ANSWER 4 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI 1,2-Substituted imidazolyl compounds for the treatment of inflammation
GI



I



II

AB A class of imidazolyl compds., which are selective inhibitors of cyclooxygenase 2 (COX 2), is described. The compds. are useful in treating inflammation and related disorders (**arthritis**, fever, and pain). Compds. of particular interest are I [R3 = H, (un)substituted alkyl, aralkyl, heterocycloalkyl, acyl, cyano, alkoxy, alkylthio, cycloalkoxy, halo, substituted carbonyl, sulfonyl, oxy, thio, aryl, and heteroaryl; R7 = alkyl or amino; R8 = ≥ 1 of H, halo, alkyl, haloalkyl, alkoxy, amino, haloalkoxy, cyano, CO2H, OH, hydroxyalkyl, alkoxyalkyl, alkylamino, nitro, and alkylthio], as well as certain heterocyclic analogs. For instance, condensation of 4-(methylsulfonyl)aniline-HCl with 3-cyanopyridine in the presence of Me3Al (34%), followed by cyclization of the resultant amidine with BrCH2COCF3 (60%), and dehydration of the obtained hydroxydihydroimidazole derivative using p-MeC6H4SO3H (23%), gave title compound II. In the carrageenan-induced rat paw edema and analgesia tests, II gave 57% inhibition of edema at 30 mg/kg orally, and 51% inhibition of hyperalgesic foot withdrawal at 10 mg/kg orally. Inhibition data for recombinant COX 1 and 2 are also given.

AN 1996:363276 CAPLUS
DN 125:33646
TI 1,2-Substituted imidazolyl compounds for the treatment of inflammation
IN Khanna, Ish K.; Weier, Richard M.; Collins, Paul W.; Yu, Yi; Xu, Xiangdong; Huff, Renee M.; Partis, Richard A.; Koszyk, Francis J.
PA G.D. Searle and Co., USA
SO PCT Int. Appl., 249 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9603388	A1	19960208	WO 1995-US9506	19950727 <--
	W: AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LU, LV, MD,				

MG, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TT
RW: KE, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG

	US 5616601	A	19970401	US 1995-464154	19950605 <--
	AU 9532025	A1	19960222	AU 1995-32025	19950727 <--
	EP 772600	A1	19970514	EP 1995-928164	19950727 <--
	EP 772600	B1	20020918		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, NL, PT, SE				
	JP 10503211	T2	19980324	JP 1995-505972	19950727 <--
	AT 224374	E	20021015	AT 1995-928164	19950727
	AU 767993	B2	20031127	AU 2001-11100	20010109
	US 2003036557	A1	20030220	US 2001-4944	20011205
	US 6613789	B2	20030902		
	US 2005096368	A1	20050505	US 2003-653399	20030902
	US 2005256120	A1	20051117	US 2005-183016	20050715
PRAI	US 1994-282395	A	19940728		
	US 1995-464154	A	19950605		
	WO 1995-US9506	W	19950727		
	AU 1997-15739	A3	19970124		
	WO 1997-US300	W	19970124		
	US 1999-101493	B1	19990602		
	US 2001-4944	A1	20011205		
	US 2003-653399	A1	20030902		
OS	MARPAT 125:33646				

L7 ANSWER 5 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Dietary supplement for pain relief
AB A dietary supplement containing sources of vitamins B3, B5, and/or B6, D-phenylalanine, glucosamine sulfate, and optionally mucopolysaccharides such as chondroitin sulfate and shark cartilage can provide relief of joint or muscular pain, e.g. **arthritis.** Thus, a tablet formulation contained pantothenic acid 100, shark cartilage 100, DL-phenylalanine 50, chondroitin sulfate 50, glucosamine sulfate 50 mg, and conventional tableting additives.
AN 1995:958356 CAPLUS
DN 123:350289
TI Dietary supplement for pain relief
IN Woodward, Robert John
PA UK
SO Brit. UK Pat. Appl., 9 pp.
CODEN: BAXXDU
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 2286528	A1	19950823	GB 1994-3063	19940217 <--
	GB 2286528	B2	19980916		
PRAI	GB 1994-3063		19940217		

L7 ANSWER 6 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Heteroaryl-Fused 2-Phenylisothiazolone Inhibitors of Cartilage Breakdown
GI



I

AB The synthesis, biol. evaluation, and structure-activity relationships of a series of N-Ph heteroaryl-fused isothiazolones, e.g. I (R = aryl) are described. These isothiazolones have been shown to exhibit potent, dose-dependent inhibition of IL-1β-induced breakdown of proteoglycan in a cartilage organ culture assay. This effect is likely due to inhibition of MMP activation and a consequent reduction in MMP activity following IL-1β stimulation. Thus these compds. potentially represent simple, non-peptidic disease-modifying agents for the treatment of arthritic diseases. To examine the effects of structure on in vitro activity, three general features of the mols. were varied, substituents on the pendant N-Ph group, the position of ring fusion to the isothiazolone, and substituents on the fused ring peri to the isothiazolone sulfur.
AN 1994:605254 CAPLUS
DN 121:205254
TI Heteroaryl-Fused 2-Phenylisothiazolone Inhibitors of Cartilage Breakdown
AU Wright, Stephen W.; Petraitis, Joseph J.; Abelman, Matthew M.; Batt, Douglas G.; Bostrom, Lori L.; Corbett, Ronald L.; Decicco, Carl P.; Di Meo, Susan V.; Freimark, Bruce; et al.
CS Inflammatory Diseases Research, DuPont Merck Pharmaceutical Company, Wilmington, DE, 19880-0353, USA
SO Journal of Medicinal Chemistry (**1994**), 37(19), 3071-8
CODEN: JMCMAR; ISSN: 0022-2623
DT Journal
LA English

L7 ANSWER 7 OF 7 CAPLUS COPYRIGHT 2006 ACS on STN
TI Transformations in the pyridine series. A simple preparation of 3-methyl-4-phenylpyridine and corresponding 2-carboxamides
GI



II

AB 3-Methyl-4-phenylpyridine (I) was prepared in 96% yield by Huang-Minlon reduction of 4-phenyl-3-pyridinecarboxaldehyde. I was carboxylated followed by amidation to give its 1-pyridinecarboxamides, e.g. II. At 30 mg/kg II reduced edema in the rat adjuvant **arthritis** test by 17%.
AN 1980:550093 CAPLUS
DN 93:150093
TI Transformations in the pyridine series. A simple preparation of 3-methyl-4-phenylpyridine and corresponding 2-carboxamides
AU Harrison, Ernest A., Jr.; Rice, Kenner C.; Rogers, Michael E.
CS Natl. Inst. Arthritis Metab. Dig. Dis., NIH, Bethesda, MD, 20205, USA
SO Heterocycles (**1980**), 14(6), 813-16
CODEN: HTCYAM; ISSN: 0385-5414
DT Journal
LA English

=> s pyridinedicarboxamide
L8 309 PYRIDINEDICARBOXAMIDE

=> s L8 and inflamm?
241376 INFLAMM?
L9 5 L8 AND INFLAMM?

=> s L8 and ?nflamm?

```
        260115 ?NFLAMM?
L10           5 L8 AND ?NFLAMM?

=> s L10 and py<2003
      22795154 PY<2003
L11           5 L10 AND PY<2003

=> d L11 1-5 ti abs bib

L11  ANSWER 1 OF 5  CAPLUS  COPYRIGHT 2006 ACS on STN
TI   Preparation of pyridinedicarboxamide and -dicarboxylic acid
     derivatives as selective MMP-13 matrix metalloproteinase inhibitors with
     therapeutic uses
GI
```



I

```
AB   Selective MMP-13 inhibitors are pyridine derivs. (I; e.g.
     pyridine-2,4-dicarboxylic acid bis(3-methoxybenzylamide)) or a
     pharmaceutically acceptable salt thereof, wherein: R1 and R2 independently
     are H, halo, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C2-C6 alkenyl, C2-C6
     alkynyl, NO2, NR4R5, CN, or CF3; E is independently O or S; A and B
     independently are OR4 or NR4R5; R4 and R5 independently are H, C1-C6
     alkyl, C2-C6 alkenyl, C2-C6 alkynyl, (CH2)n aryl, (CH2)n cycloalkyl,
     (CH2)n heteroaryl, or R4 and R5 when taken together with the N to which
     they are attached complete a 3- to 8-membered ring containing C atoms and
     optionally containing a heteroatom selected from O, S, or NH, and optionally
     substituted or unsubstituted; n is 0 to 6.  Although I and other Markush
     structures in the patent show 2,4- derivs., many specific 3,5- derivs. are
     included in the claims and examples.  Combinatorial and non-combinatorial
     methods were used to prepare numerous claimed compds. and characterization
     data is reported for about 90 compds.  IC50 values for various claimed
     compds. show the selectivity towards MMP-13 vs. MMP-1 and MMP-3 and the
     potent MMP-13 inhibitory activity (e.g. 0.033 μM for
     pyridine-2,4-dicarboxylic acid bis[((1,3-benzodioxol-5-yl)methyl)amide]).
AN   2002:637657  CAPLUS
DN   137:185420
TI   Preparation of pyridinedicarboxamide and -dicarboxylic acid
     derivatives as selective MMP-13 matrix metalloproteinase inhibitors with
     therapeutic uses
IN   Barvian, Nicole Chantel; Connor, David Thomas; O'brien, Patrick Michael;
     Ortwine, Daniel Fred; Patt, William Chester; Shuler, Kevon Ray; Wilson,
     Michael William
PA   Warner-Lambert Company, USA
SO   PCT Int. Appl., 68 pp.
     CODEN: PIXXD2
DT   Patent
LA   English
FAN.CNT 1
     PATENT NO.          KIND   DATE        APPLICATION NO.        DATE
     ---------------     ----   --------    --------------------   --------
PI   WO 2002064568        A1    20020822    WO 2002-IB345          20020204 <--
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
             GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
```

LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA,
UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH,
CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR,
BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

CA 2434982	AA	20020822	CA 2002-2434982	20020204	<--
EP 1362033	A1	20031119	EP 2002-716263	20020204	
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR					
EE 200300391	A	20031215	EE 2003-391	20020204	
BR 2002007863	A	20040427	BR 2002-7863	20020204	
JP 2004529878	T2	20040930	JP 2002-564501	20020204	
CN 1537101	A	20041013	CN 2002-804945	20020204	
US 2002161000	A1	20021031	US 2002-71073	20020208	<--
US 6881743	B2	20050419			
ZA 2003006041	A	20041105	ZA 2003-6041	20030805	
NO 2003003570	A	20030812	NO 2003-3570	20030812	
BG 108089	A	20050131	BG 2003-108089	20030813	
US 2004209922	A1	20041021	US 2004-842863	20040510	
US 7015237	B2	20060321			
PRAI US 2001-268781P	P	20010214			
WO 2002-IB345	W	20020204			
US 2002-71073	A3	20020208			

OS MARPAT 137:185420
RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L11 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI New N-aryl-2,3-pyridinedicarboxamides: chemical and pharmacological studies
AB Six title compds. were prepared by dehydration of 2,3-pyridinedicartboxylic acid with acetic anhydride and subsequent reactions with aromatic amines to yield amides. The products were characterized by spectrometric methods and their toxicity and analgesic and anti-**inflammatory** effects were tested in male mice. Antibacterial and antifungal activities were tested in vitro.
AN 1992:440006 CAPLUS
DN 117:40006
TI New N-aryl-2,3-pyridinedicarboxamides: chemical and pharmacological studies
AU Albuquerque, C. N.; Bacha, C. T. M.; Schapoval, E. E. S.; Loiseau, P.; Flores, S. B.
CS Fac. Farmacia, UFRGS, Porto Alegre, Brazil
SO Revista Brasileira de Farmacia (**1991**), 72(2), 31-3
CODEN: RBFAAH; ISSN: 0370-372X
DT Journal
LA Portuguese

L11 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pyridinedicarboxamides
GI



I


II

AB Title compds. I (R = halo, NHNH2, amino, OR1, SR1; R1 = alkyl, cycloalkyl, alkenyl, alkynyl, aralkyl, Ph, pyridyl), useful as **inflammation**

inhibitors, analgesics, antithrombotics, and neoplasm inhibitors (no data), were prepared Thus, treating 8 g II with MeOH and 40% MeNH2 gave 7.1 g I (R = Cl).

AN 1984:51459 CAPLUS
DN 100:51459
TI Pyridinedicarboxamides
PA Chugai Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 5 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 58159465	A2	19830921	JP 1982-40902	19820317 <--
JP 01042267	B4	19890911		
PRAI JP 1982-40902		19820317		

L11 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI Pyridinedicarboxamides
GI



I

AB Two pyridinedicarboxamides I [R = 2-HO2CC6H4 (II), 2-pyridyl] were prepared by condensation of 2,6-pyridinedicarbonyl dichloride (III) with 2-H2NC6H4CO2H (IV) or 2-aminopyridine. I had **antiinflammatory**, antipyretic, and analgesic activities (no data). Thus, 2.04 g III was treated with 2.7 g IV and 1 g NaOH at 20° to give 1.9 g II.

AN 1977:468163 CAPLUS
DN 87:68163
TI Pyridinedicarboxamides
IN Matsuzaki, Meiki; Okabe, Hiroshi; Tanaka, Seishiro
PA Banyu Pharmaceutical Co., Ltd., Japan
SO Jpn. Kokai Tokkyo Koho, 2 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI JP 52033676	A2	19770314	JP 1975-108495	19750909 <--
PRAI JP 1975-108495	A	19750909		

L11 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2006 ACS on STN
TI **Antiinflammatory** p-aminosalicylic acid derivatives
GI For diagram(s), see printed CA Issue.
AB Amines I (R1 = Ph, pyridyl, thienyl, pyrrolyl, furyl; R2 = H, Me, Et, Bu, Pr, iso-Pr, Na, K, Ca, Mg, Al) were prepared by acylating 4-aminosalicyclic acid (II) or its esters with acids R1CO2H or acid chlorides R1COCl. I were effective against carrageenin-induced edema in rats (ED30 20-120 mg/kg) and had low toxicity in mice (LD50 >3 g/kg). Thus, 3.8 g II in aqueous NaOH was acylated with 3.04 g 2,6-pyridinedicarbonyl chloride to give 71.1% III (R2 = H), converted to di-Na salt. Also prepared was III (R2 = Et).

AN 1975:409805 CAPLUS
DN 83:9805
TI **Antiinflammatory** p-aminosalicylic acid derivatives
IN Matsuzaki, Meiki; Okabe, Hiroshi; Tanaka, Seishiro; Nakamura, Koichi;

Yoshida, Akio
PA Banyu Pharmaceutical Co., Ltd.
SO Jpn. Kokai Tokkyo Koho, 4 pp.
CODEN: JKXXAF
DT Patent
LA Japanese
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	JP 49110641	A2	19741022	JP 1973-28009	19730312 <--
	JP 57015584	B4	19820331		
PRAI	JP 1973-28009	A	19730312		

=> s pyridinedicarboxamide and (antibiotic or antimicrobial or antiviral)
309 PYRIDINEDICARBOXAMIDE
124384 ANTIBIOTIC
62249 ANTIMICROBIAL
53225 ANTIVIRAL
L12 2 PYRIDINEDICARBOXAMIDE AND (ANTIBIOTIC OR ANTIMICROBIAL OR ANTIVIRAL)

=> d L12 1-2 ti abs bib

L12 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI New N-aryl-2,3-pyridinedicarboxamides: chemical and pharmacological studies
AB Six title compds. were prepared by dehydration of 2,3-pyridinedicartboxylic acid with acetic anhydride and subsequent reactions with aromatic amines to yield amides. The products were characterized by spectrometric methods and their toxicity and analgesic and anti-inflammatory effects were tested in male mice. Antibacterial and antifungal activities were tested in vitro.
AN 1992:440006 CAPLUS
DN 117:40006
TI New N-aryl-2,3-pyridinedicarboxamides: chemical and pharmacological studies
AU Albuquerque, C. N.; Bacha, C. T. M.; Schapoval, E. E. S.; Loiseau, P.; Flores, S. B.
CS Fac. Farmacia, UFRGS, Porto Alegre, Brazil
SO Revista Brasileira de Farmacia (1991), 72(2), 31-3
CODEN: RBFAAH; ISSN: 0370-372X
DT Journal
LA Portuguese

L12 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2006 ACS on STN
TI Kanamycin derivatives
AB Kanamycin (I) derivs. which maintain high blood levels of the **antibiotic** for prolonged periods of time are prepared by treating I with at least 4 moles of a monocyclic aromatic monoaldehyde. Thus, 11.4 g. I in 50 ml. H2O added to 7 g. p-ClC6H4CHO in 50 ml. MeOH caused the temperature to rise to 40-50° and an oil to deposit. The oil crystallized on scratching. The product, after standing overnight, was filtered off, treated with C in hot MeOH and the MeOH was diluted with H2O until crystallization was initiated. The crystalline product was dried 2 hrs. at 61° in vacuo to yield the I tetrakis(p-chlorobenzylidene) derivative (II) (containing 3.88% H2O), m. 213-16° (decomposition). Several analogs of II were prepared similarly (starting aldehyde and m.p. of analog given): o-HOC6H4CHO, above 165°(decomposition); p-HOC6H4CHO, 193-6° (decomposition); p-Me2NC6H4CHO, 255-8°; 3,4-(MeO)2C6H3CHO, 173-5° (decomposition); BzH, 235-7° (decomposition); p-MeC6H4CHO, -; p-O2NC6H4CHO, -; 2-pyridinecarboxaldehyde, -. Derivs. of furfural and 2-thiophenecarboxaldehyde were also used.
AN 1961:2773 CAPLUS

DN 55:2773
OREF 55:574g-i
TI Kanamycin derivatives
PA Bristol Laboratories International, S.A.
DT Patent
LA Unavailable
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	GB 833851		19600504	GB	
	DE 1141272			DE	

=> file medline

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	109.65	109.86

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-13.50	-13.50

FILE 'MEDLINE' ENTERED AT 16:07:22 ON 25 APR 2006

FILE LAST UPDATED: 22 APR 2006 (20060422/UP). FILE COVERS 1950 TO DATE.

On December 11, 2005, the 2006 MeSH terms were loaded.

The MEDLINE reload for 2006 is now (26 Feb.) available. For details on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>). See also:

http://www.nlm.nih.gov/mesh/
http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

OLDMEDLINE is covered back to 1950.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2006 vocabulary.

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> file registry

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.39	110.25

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-13.50

FILE 'REGISTRY' ENTERED AT 16:07:37 ON 25 APR 2006

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0
DICTIONARY FILE UPDATES: 24 APR 2006 HIGHEST RN 881733-90-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 6, 2006

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

```
**********************************************************************
*                                                                    *
* The CA roles and document type information have been removed from *
* the IDE default display format and the ED field has been added,    *
* effective March 20, 2005.  A new display format, IDERL, is now     *
* available and contains the CA role and document type information.  *
*                                                                    *
**********************************************************************
```

Structure search iteration limits have been increased. See HELP SLIMITS for details.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

```
=> s valdecoxib/cn
L13           1 VALDECOXIB/CN

=> sel L13
E1 THROUGH E6 ASSIGNED

=> file medline
COST IN U.S. DOLLARS                          SINCE FILE      TOTAL
                                                 ENTRY    SESSION
FULL ESTIMATED COST                               5.53     115.78

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)    SINCE FILE      TOTAL
                                                 ENTRY    SESSION
CA SUBSCRIBER PRICE                               0.00     -13.50

FILE 'MEDLINE' ENTERED AT 16:07:53 ON 25 APR 2006

 FILE LAST UPDATED: 22 APR 2006 (20060422/UP).  FILE COVERS 1950 TO DATE.

 On December 11, 2005, the 2006 MeSH terms were loaded.

 The MEDLINE reload for 2006 is now (26 Feb.) available.  For details
 on the 2006 reload, enter HELP RLOAD at an arrow prompt (=>).
 See also:

    http://www.nlm.nih.gov/mesh/
    http://www.nlm.nih.gov/pubs/techbull/nd04/nd04_mesh.html
    http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_med_data_changes.html
    http://www.nlm.nih.gov/pubs/techbull/nd05/nd05_2006_MeSH.html

 OLDMEDLINE is covered back to 1950.

 MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the
 MeSH 2006 vocabulary.

 This file contains CAS Registry Numbers for easy and accurate
 substance identification.

=> s E1-E6
```

```
           14 BEXTRA/BI
        99415 "SC"/BI
            1 "65872"/BI
            0 "SC 65872"/BI
                (("SC"(W)"65872")/BI)
          249 VALDECOXIB/BI
            0 VALECOXIB/BI
            0 181695-72-7/BI
      2273123 "4"/BI
      2216267 "5"/BI
       163493 "METHYL"/BI
      2986572 "3"/BI
           19 "PHENYLISOXAZOL"/BI
      2273123 "4"/BI
        20531 "YL"/BI
          426 "BENZENESULFONAMIDE"/BI
            1 "4-(5-METHYL-3-PHENYLISOXAZOL-4-YL)BENZENESULFONAMIDE"/BI
                (("4"(W)"5"(W)"METHYL"(W)"3"(W)"PHENYLISOXAZOL"(W)"4"(W)"YL"(W
                )"BENZENESULFONAMIDE")/BI)
L14         250 (BEXTRA/BI OR "SC 65872"/BI OR VALDECOXIB/BI OR VALECOXIB/BI OR
                181695-72-7/BI OR "4-(5-METHYL-3-PHENYLISOXAZOL-4-YL)BENZENESULF
               ONAMIDE"/BI)

=> s L14 and (HIV or (human(w)immunodeficiency(w)virus))
      157944 HIV
     1381335 HUMAN
      122706 IMMUNODEFICIENCY
      411496 VIRUS
       48241 HUMAN(W)IMMUNODEFICIENCY(W)VIRUS
L15         4 L14 AND (HIV OR (HUMAN(W)IMMUNODEFICIENCY(W)VIRUS))

=> d L15 1-4 ti abs bib

L15  ANSWER 1 OF 4     MEDLINE on STN
TI   Gateways to clinical trials.
AB   Gateways to Clinical Trials is a guide to the most recent clinical trials
     in current literature and congresses.  The data in the following tables
     have been retrieved from the Clinical Trials Knowledge Area of Prous
     Science Integrity, the drug discovery and development portal,
     http://integrity.prous.com.  This issue focuses on the following selection
     of drugs: Abiraterone acetate, acyline, adalimumab, adenosine
     triphosphate, AEE-788, AIDSVAX gp120 B/B, AK-602, alefacept, alemtuzumab,
     alendronic acid sodium salt, alicaforsen sodium, alprazolam, amdoxovir,
     AMG-162, aminolevulinic acid hydrochloride, aminolevulinic acid methyl
     ester, aminophylline hydrate, anakinra, anecortave acetate, anti-CTLA-4
     MAb, APC-8015, aripiprazole, aspirin, atazanavir sulfate, atomoxetine
     hydrochloride, atorvastatin calcium, atrasentan, AVE-5883, AZD-2171;
     Betamethasone dipropionate, bevacizumab, bimatoprost, biphasic human
     insulin (prb), bortezomib, BR-A-657, BRL-55730, budesonide, busulfan;
     Calcipotriol, calcipotriol/betamethasone dipropionate, calcium folinate,
     capecitabine, capravirine, carmustine, caspofungin acetate, cefdinir,
     certolizumab pegol, CG-53135, chlorambucil, ciclesonide, ciclosporin,
     cisplatin, clofarabine, clopidogrel hydrogensulfate, clozapine,
     co-trimoxazole, CP-122721, creatine, CY-2301, cyclophosphamide, cypher,
     cytarabine, cytolin; D0401, darbepoetin alfa, darifenacin hydrobromide,
     DASB, desipramine hydrochloride, desloratadine, desvenlafaxine succinate,
     dexamethasone, didanosine, diquafosol tetrasodium, docetaxel, doxorubicin
     hydrochloride, drotrecogin alfa (activated), duloxetine hydrochloride,
     dutasteride; Ecallantide, efalizumab, efavirenz, eletriptan,
     emtricitabine, enfuvirtide, enoxaparin sodium, estramustine phosphate
     sodium, etanercept, ethinylestradiol, etonogestrel,
     etonogestrel/ethinylestradiol, etoposide, exenatide; Famciclovir,
     fampridine, febuxostat, filgrastim, fludarabine phosphate, fluocinolone
     acetonide, fluorouracil, fluticasone propionate, fluvastatin sodium,
     fondaparinux sodium; Gaboxadol, gamma-hydroxybutyrate sodium, gefitinib,
```

gelclair, gemcitabine, gemfibrozil, glibenclamide, glyminox; Haloperidol, heparin sodium, HPV 16/HPV 18 vaccine, human insulin, human insulin; Icatibant, imatinib mesylate, indium 111 (111In) ibritumomab tiuxetan, infliximab, INKP-100, iodine (I131) tositumomab, IoGen, ipratropium bromide, ixabepilone; L-870810, lamivudine, lapatinib, laquinimod, latanoprost, levonorgestrel, licochalcone a, liposomal doxorubicin, lopinavir, lopinavir/ritonavir, lorazepam, lovastatin; Maraviroc, maribavir, matuzumab, MDL-100907, melphalan, methotrexate, methylprednisolone, mitomycin, mitoxantrone hydrochloride, MK-0431, MN-001, MRKAd5 **HIV**-1 gag/pol/nef, MRKAd5gag, MVA.HIVA, MVA-BN Nef, MVA-Muc1-IL-2, mycophenolate mofetil; Nelfinavir mesilate, nesiritide, NSC-330507; Olanzapine, olmesartan medoxomil, omalizumab, oral insulin, osanetant; PA-457, paclitaxel, paroxetine, paroxetine hydrochloride, PCK-3145, PEG-filgrastim, peginterferon alfa-2a, peginterferon alfa-2b, perillyl alcohol, pexelizumab, pimecrolimus, pitavastatin calcium, porfiromycin, prasterone, prasugrel, pravastatin sodium, prednisone, pregabalin, prinomastat, PRO-2000, propofol, prostate cancer vaccine; Rasagiline mesilate, rhBMP-2/ACS, rhBMP-2/BCP, rhC1, ribavirin, rilpivirine, ritonavir, rituximab, Ro-26-9228, rosuvastatin calcium, rosuvastatin sodium, rubitecan; Selodenoson, simvastatin, sirolimus, sitaxsentan sodium, sorafenib, SS(dsFv)-PE38, St. John's Wort extract, stavudine; Tacrolimus, tadalafil, tafenoquine succinate, talaglumetad, tanomastat, taxus, tegaserod maleate, telithromycin, tempol, tenofovir, tenofovir disoproxil fumarate, testosterone enanthate, TH-9507, thalidomide, tigecycline, timolol maleate, tiotropium bromide, tipifarnib, torcetrapib, trabectedin, travoprost, travoprost/timolol, treprostinil sodium; **Valdecoxib**, vardenafil hydrochloride hydrate, varenicline, VEGF-2 gene therapy, venlafaxine hydrochloride, vildagliptin, vincristine sulfate, voriconazole, VRX-496, VX-385; Warfarin sodium; Ximelagatran; Yttrium 90 (90Y) ibritumomab tiuxetan; Zanolimumab, zidovudine.

AN 2005417782 MEDLINE
DN PubMed ID: 16082422
TI Gateways to clinical trials.
AU Bayes M; Rabasseda X; Prous J R
CS Department of Pharmacology, Prous Science, Barcelona, Spain.. mbayes@prous.com
SO Methods and findings in experimental and clinical pharmacology, (2005 Jun) Vol. 27, No. 5, pp. 331-72.
Journal code: 7909595. ISSN: 0379-0355.
CY Spain
DT Bibliography
LA English
FS Priority Journals
EM 200509
ED Entered STN: 6 Aug 2005
Last Updated on STN: 28 Sep 2005
Entered Medline: 27 Sep 2005

L15 ANSWER 2 OF 4 MEDLINE on STN
TI Gateways to clinical trials.
AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity. prous.com. This issue focuses on the following selection of drugs: ABX-IL-8, Acclaim, adalimumab, AGI-1067, alagebrium chloride, alemtuzumab, Alequel, Androgel, anti-IL-12 MAb, AOD-9604, aripiprazole, atomoxetine hydrochloride; Biphasic insulin aspart, bosentan, botulinum toxin type B, bovine lactoferrin, brivudine; Cantuzumab mertansine, CB-1954, CDB-4124, CEA-TRICOM, choriogonadotropin alfa, cilansetron, CpG-10101, CpG-7909, CTL-102, CTL-102/CB-1954; DAC:GRF, darbepoetin alfa, davanat-1, decitabine, del-1 Genemedicine, dexanabinol, dextofisopam, dnaJP1, dronedarone hydrochloride, dutasteride;

Ecogramostim, eletriptan, emtricitabine, EPI-hNE-4, eplerenone, eplivanserin fumarate, erlotinib hydrochloride, ertapenem sodium, escitalopram oxalate, esomeprazole magnesium, etoricoxib, ezetimibe; Falecalcitriol, fingolimod hydrochloride; Gepirone hydrochloride; HBV-ISS, HSV-2 theracine, human insulin; Imatinib mesylate, Indiplon, insulin glargine, ISAtx-247; L612 HuMAb, levodopa/carbidopa/entacapone, lidocaine/prilocaine, LL-2113AD, lucinactant, LY-156735; Meclinertant, metelimumab, morphine hydrochloride, morphine-6-glucuronide; Natalizumab, nimotuzumab, NX-1207, NYVAC-**HIV** C; Omalizumab, onercept, osanetant; PABA, palosuran sulfate, parathyroid hormone (human recombinant), parecoxib sodium, PBI-1402, PCK-3145, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pemetrexed disodium, pimecrolimus, PINC, pregabalin; Ramelteon, rasagiline mesilate, rasburicase, rimonabant hydrochloride, RO-0098557, rofecoxib, rosiglitazone maleate/metformin hydrochloride; Safinamide mesilate, SHL-749, sitaxsentan sodium, sparfosic acid, SprayGel, squalamine, St. John's Wort extract, synthetic human secretin; Taxus, telavancin hydrochloride, telithromycin, temoporfin, tenofovir disoproxil fumarate, tenofovir disoproxil fumarate/emtricitabine, teriparatide, testosterone gel, TG-1024, tirapazamine, travoprost, travoprost/timolol; **Valdecoxib**, valganciclovir hydrochloride, voriconazole; Ximelagatran.

AN 2005200517 MEDLINE
DN PubMed ID: 15834452
TI Gateways to clinical trials.
AU Bayes M; Rabasseda X; Prous J R
SO Methods and findings in experimental and clinical pharmacology, (2005 Apr) Vol. 27, No. 3, pp. 193-219.
Journal code: 7909595. ISSN: 0379-0355.
CY Spain
DT Bibliography
LA English
FS Priority Journals
EM 200507
ED Entered STN: 19 Apr 2005
Last Updated on STN: 16 Jul 2005
Entered Medline: 15 Jul 2005

L15 ANSWER 3 OF 4 MEDLINE on STN
TI Gateways to clinical trials.
AB Gateways to Clinical Trials is a guide to the most recent clinical trials reported in current literature and congresses. The data in the following tables have been retrieved from the Clinical Trials Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs:[188Re]-HDD; A-179578, adalimumab, AK-602, albumin interferon alfa, alfimeprase, amelubant, anakinra, anti-CD2 MAb, APD-356, aripiprazole, atvogen; Bimatoprost, bimosiamose, BLP-25, brivaracetam; Caspofungin acetate, cilansetron, CMV vaccine (bivalent), conivaptan hydrochloride, Cypher; Darbepoetin alfa, darifenacin hydrobromide, D-D4FC, decitabine, dnaJP1, doranidazole, dronedarone hydrochloride; Efalizumab, efaproxiral sodium, emtricitabine, Endeavor, entecavir, erlotinib hydrochloride, escitalopram oxalate, etoricoxib, etravirine, ezetimibe; Fampridine, fenretinide, ferumoxtran-10, forodesine hydrochloride; Gantacurium chloride, gemi-floxacin mesilate, Glyminox, GW-501516; HBV-ISS, hepavir B, human insulin, HuMax-CD20, hyaluronic acid, HyCAMP; Icatibant, IDEA-070, IGN-311, imatinib mesylate, insulin detemir, insulin glargine, insulin glulisine; Lapatinib, lasofoxifene tartrate, LB-80380, liarozole fumarate, liposome encapsulated doxorubicin, lumiracoxib, LY-570310; MC-1, melatonin, merimepodib, metanicotine, midostaurin; Natalizumab, nicotine conjugate vaccine, NYVAC-**HIV** C; Patupilone, peginterferon alfa-2a, peginterferon alfa-2b, peginterferon alfa-2b/ribavirin, pelitinib, Peru-15, pexelizumab, PHP, pimecrolimus, prednisolone sodium metasulfobenzoate; Recombinant alfa1-antitrypsin (AAT), retigabine, rHA influenza vaccine, rifalazil, rofecoxib,

rosiglitazone maleate/Metformin hydrochloride, rostaporfin, rosuvastatin calcium, rubitecan; Selenite sodium, semilente insulin, SMP-797, sorafenib; Talampanel, tenofovir disoproxil fumarate, TER-199, tiotropium bromide, torcetrapib, treprostinil sodium, TTA; ValboroPro, **valdecoxib**, val-mCyd, valtorcitabine dihydrochloride: XP-828L.

AN 2005200505 MEDLINE
DN PubMed ID: 15834459
TI Gateways to clinical trials.
AU Bayes M; Rabasseda X; Prous J R
SO Methods and findings in experimental and clinical pharmacology, (2005 Jan-Feb) Vol. 27, No. 1, pp. 49-77.
Journal code: 7909595. ISSN: 0379-0355.
CY Spain
DT Bibliography
LA English
FS Priority Journals
EM 200506
ED Entered STN: 19 Apr 2005
Last Updated on STN: 22 Jun 2005
Entered Medline: 21 Jun 2005

L15 ANSWER 4 OF 4 MEDLINE on STN
TI Gateways to clinical trials.
AB Gateways to Clinical Trials is a guide to the most recent clinical trials in current literature and congresses. The data in the following tables has been retrieved from the Clinical Studies Knowledge Area of Prous Science Integrity, the drug discovery and development portal, http://integrity.prous.com. This issue focuses on the following selection of drugs: 166Ho-DOTMP 5A8; A-179578, abetimus sodium, adefovir dipivoxil, AGI-1067, AIDSVAX gp120 B/B, AK-602, alefacept alemtuzumab, aliskiren fumarate, ALVAC vCP1433, ALVAC vCP1452, anecortave acetate, arzoxifene hydrochloride, atazanavir sulfate, atlizumab, avasimibe; Binodenoson, BMS-488043; Choriogonadotropin alfa, ciclesonide, COL-1621, CVT-3146, CVT-E002, Cypher; Daptomycin, darbepoetin alfa, darunavir, D-D4FC, deferasirox, desloratadine, desmoteplase, duloxetine hydrochloride, DX-9065a; E-5564, efalizumab, emfilermin, emivirine, emtricitabine, enfuvirtide, estradiol acetate, ezetimibe; Frovatriptan; Gallium maltolate, gefitinib; **HIV**-1 Immunogen, human insulin; Iguratimod, IL-4/IL-13 Trap, imatinib mesylate, inhaled insulin, insulin glargine, irofulven, ISS-1018, ivabradine hydrochloride; Lutropin alfa; Melatonin; Nesiritide; O6-Benzylguanine, omapatrilat, oritavancin, ospemifene; Parecoxib sodium, peginterferon alfa-2a, pexelizumab, pimecrolimus, pirfenidone, pramlintide acetate, prasterone sulfate PT-141; Rasburicase, razaxaban hydrochloride, recombinant malaria vaccine, rhBMP-2/ACS, roflumilast, rosiglitazone maleate/metformin hydrochloride, rotavirus vaccine; SCH-D, sitaxsentan sodium, solifenacin succinate; Targinine hydrochloride, taxus, TER-199, tramadol hydrochloride/acetaminophen; **Valdecoxib**, valganciclovir hydrochloride, vatalanib succinate, VEG Trap(R1R2); Ximelagatran; Yttrium Y90 Epratuzumab.
AN 2004414825 MEDLINE
DN PubMed ID: 15319808
TI Gateways to clinical trials.
AU Bayes M; Rabasseda X; Prous J R
CS Prous Science, S.A., Barcelona, Spain.. mbayes@prous.com
SO Methods and findings in experimental and clinical pharmacology, (2004 May) Vol. 26, No. 4, pp. 295-318.
Journal code: 7909595. ISSN: 0379-0355.
CY Spain
DT Bibliography
LA English
FS Priority Journals
EM 200501
ED Entered STN: 21 Aug 2004

Last Updated on STN: 26 Jan 2005
Entered Medline: 25 Jan 2005

```
=> s L14 and cancer
        536885 CANCER
L16           6 L14 AND CANCER

=> d L16 1-6 ti

L16  ANSWER 1 OF 6      MEDLINE on STN
TI   Update on nonsteriodal anti-inflammatory drugs.

L16  ANSWER 2 OF 6      MEDLINE on STN
TI   Gateways to clinical trials.

L16  ANSWER 3 OF 6      MEDLINE on STN
TI   Researchers plan to continue to study COX-2 inhibitors in cancer
     treatment and prevention.

L16  ANSWER 4 OF 6      MEDLINE on STN
TI   Differential effects of selective COX-2 inhibitors on cell cycle
     regulation and proliferation of glioblastoma cell lines.

L16  ANSWER 5 OF 6      MEDLINE on STN
TI   Anti-hyperalgesic activity of the cox-2 inhibitor lumiracoxib in a model
     of bone cancer pain in the rat.

L16  ANSWER 6 OF 6      MEDLINE on STN
TI   Cyclooxygenase-2: from arthritis treatment to new indications for the
     prevention and treatment of cancer.


=> s L16 and py<2003
      13951807 PY<2003
                (PY<20030000)
L17           0 L16 AND PY<2003

=> logoff
ALL L# QUERIES AND ANSWER SETS ARE DELETED AT LOGOFF
LOGOFF? (Y)/N/HOLD:y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    2.44     118.22

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    0.00     -13.50

STN INTERNATIONAL LOGOFF AT 16:10:14 ON 25 APR 2006
```